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SUMMARY 
Pharmacoepidemiology is defined as the study of the utilization and effects of drugs 
in large human populations. Beside its classical role in the evaluation of drug safety 
after marketing, pharmacoepidemiology is increasingly gaining importance in the pre-
marketing phase of the drug development process, where it can provide useful 
information on the natural history of the disease a drug is being developed to treat. 
Alzheimer’s disease (AD) is one of the most disabling and burdensome health 
conditions worldwide. It is the most common form of dementia with more than 26 
million cases worldwide. Vascular dementia (VD) is the second most common 
dementia form, resulting from intracerebral vascular and circulatory pathology.  
The aim of this thesis was to increase knowledge on the natural history of AD and 
VD, thereby focusing on the effect of certain drug therapies as potential risk or 
protective factors for these diseases or complications thereof.  
The studies in this thesis were carried out using data from the United Kingdom (UK) 
based General Practice Research Database (GPRD), a large and well established 
physician-based primary care database. This database contains longitudinal records 
from several million patients representative of the UK population. The information 
recorded in the medical files includes patient demographics and characteristics (e.g. 
age, sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, and hospitalizations. 
In the first study (3.1) we identified patients aged ≥65 years with an incident 
diagnosis of AD or VD between 1998 and 2008 and assessed incidence rates (IRs) 
of AD and VD, stratified by age and sex. To each demented case patient we matched 
one dementia-free control patient and analyzed co-morbidities and drug use prior to 
the time of diagnosis. We identified 7,068 AD and 4,438 VD cases. For AD, IRs were 
higher for women than for men, but not for VD. Except for orthostatic hypotension, 
the prevalence of all cardiovascular (CV) co-morbidities and exposure to CV drugs 
was lower in patients with AD than in the corresponding controls, whereas the 
opposite was true for VD. We concluded that this may be a true finding or the result 
of diagnostic bias, i.e. that demented patients with CV diseases may be more likely to 
be diagnosed with VD than AD. 
In the second study (3.2) we studied the influence of metformin or other antidiabetic 
drugs on the risk of developing AD. We performed a case-control analysis within the 
SUMMARY 
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population of AD cases and corresponding controls identified in the first study (3.1). 
We found that long-term users of metformin had a slightly increased risk of 
developing AD as compared to non-users, but there was no consistent trend with 
increasing duration of use. Use of other antidiabetic drugs such sulfonylureas, 
thiazolidinediones, or insulin was not associated with an altered risk of developing 
AD. 
In the third (3.3) and fourth study (3.4) we followed the complete study population of 
the first study (3.1) forward in time to assess IRs of certain diseases (complications) 
of interest in patients with AD or VD and compared them to patients without 
dementia. We then performed a nested case-control analysis to identify potential risk 
factors for developing such diseases of interest. The diseases of interest in the third 
study were seizures/epilepsy and in the fourth study ischemic stroke, hemorrhagic 
stroke or transient ischemic attack (TIA). In the third study we found that seizures or 
epilepsy were substantially more common in patients with AD and VD than in 
dementia-free patients. Additionally, patients with longer standing (≥3 years) AD had 
a slightly higher risk of developing seizures or epilepsy than those with a shorter 
disease duration, while in patients with VD the contrary was observed. In the fourth 
study we found that patients with AD did not have a materially different risk of 
developing an ischemic stroke compared to patients without dementia, whereas 
patients with VD had an about twofold increased risk. AD patients receiving atypical 
antipsychotic drugs only had a higher risk of developing a TIA than AD patients not 
receiving any antipsychotic drug treatment, whereas for patients with VD there was 
no significant difference between users of atypical or typical antipsychotic drugs and 
those not receiving antipsychotic treatment. 
The GPRD is a very useful tool to conduct pharmacoepidemiological research. Its 
strengths are the large size, the population-based character of the data, and the 
opportunity to have access to original medical records. On the other hand, data on 
important confounders such as dietary or exercise habits is largely missing.   
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INTRODUCTION 
1.1 PHARMACOEPIDEMIOLOGY 
1.1.1 General aspects 
Pharmacoepidemiology is defined as the study of the utilization and effects of drugs 
in large human populations by applying reasoning, methods, and knowledge of 
epidemiology.1 It is a relatively young scientific discipline bridging between clinical 
pharmacology and epidemiology.2 The discipline has evolved against the background 
that drugs are not only beneficial, but occasionally can cause serious adverse events 
that were unexpected from pre-clinical studies or pre-marketing clinical trials.3  
Pre-marketing clinical trials are designed to study the safety and efficacy of a new 
drug, however they have several limitations. First of all they are limited in size of the 
study population. If a rare but serious adverse event for example occurs only in one 
of 10,000 patients taking a new drug, inclusion of 1,000 participants in a phase III trial 
will not detect this event. Second, pre-marketing trials are limited in study duration, 
making it difficult to detect rare adverse events that develop after a long induction 
period or cumulative drug intake. Third, these trials often include a selected study 
population, which is usually not fully representative of subsequent users of the drug.3  
One typical approach of addressing these limitations is the collection of spontaneous 
reports of adverse drug reactions during the post-marketing phase.2 However, 
determining causation in spontaneous reports may be delicate because such reports 
often do not provide enough details on co-morbidities or other drugs to rule out other 
possible causes of the adverse drug reaction.3 Pharmacoepidemiology uses a 
different approach, by performing controlled studies, which examine whether the 
adverse outcome under study occurs more often in the exposed population than in 
the non-exposed population.2  
Beside its classical role in the evaluation of drug safety after marketing, 
pharmacoepidemiology is increasingly gaining importance in the pre-marketing 
phase. A valuable application is for example the retrospective analysis of data from 
clinical phase II or III trials to identify patient risk factors for a specific adverse event, 
thereby contributing to the safety profile of a drug. Another application is the 
estimation of so-called background incidence rates of serious adverse events in 
subjects not exposed to the drug under study. This can be helpful to assess whether 
INTRODUCTION  PHARMACOEPIDEMIOLOGY 
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serious adverse events encountered during clinical trials are occurring at rates above 
the corresponding background incidence rates in subjects not exposed to the drug.4 
Additionally, epidemiological studies on the natural history of the disease a drug was 
developed to treat, performed early in the drug development process, can provide 
useful information on characteristics of the target population (e.g. in terms of co-
morbidities or drug use) or the estimated market size and help prioritize drug 
development programs.5 
 
1.1.2 Data sources 
Many pharmacoepidemiological studies are conducted as field studies, using data 
that was purposely collected to answer a specific research question. These studies 
are sometimes conducted as multi-center studies to increase the number of cases.3 
Examples include a study about the use of appetite-suppressant drugs and the risk of 
developing pulmonary hypertension6 or another study about the risk of developing 
Stevens-Johnson syndrome in association with use of different drugs.7 Alternatively, 
already existing data sources, such as multipurpose cohorts or large health 
databases, are increasingly being used. Pharmacoepidemiological studies using 
such data, have the advantage that they can be conducted faster and are less 
expensive than field studies, as the data have already been collected.3 
 
Multipurpose cohorts 
Multipurpose cohorts are designed to study many different research hypotheses. The 
study population of such cohorts usually consists of a subset of a defined population 
that was not assembled by a specific exposure, but by other factors.3 A typical 
example is the United States (US) Nurses’ Health Study, where the study population 
(initially 121,700 registered female nurses aged between 30–55 years living in one of 
11 US states) was assembled by demographic factors such age, sex, profession, and 
residence. Participants in this study were followed prospectively with follow-up 
questionnaires mailed every two years, asking them questions about different 
exposures (particularly hormone use), lifestyle factors (e.g. smoking status, exercise 
habits), and the development of chronic conditions (e.g. cancer, cardiovascular 
diseases). Later, questions about dietary habits and issues related to quality of life 
were added.8 Although the study was initially designed to investigate the association 
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between oral contraceptive use and the risk of breast cancer, it has been the 
extensively used to study other pharmacoepidemiological research questions such as 
the association between use of non-steroidal anti-inflammatory drugs (NSAIDs) and 
the risk of Parkinsons’ disease9 or oral contraceptive use and the risk of multiple 
sclerosis (MS).10  
 
Large health databases 
Large health databases contain electronically recorded patient health care data and 
constitute another important data source for pharmacoepidemiological research. 
There are two main types: administrative databases and physician-based databases. 
Administrative databases have been set up for the administration of reimbursement 
payments to health care providers.3 In North America they have been used since 
1980 for pharmacoepidemiological research.11 Administrative databases usually 
contain patient information from two or more separate files, which are linked via a 
unique and anonymized patient-identifier (e.g. the social security number). These 
files usually contain information on patient’s demographics, drug dispensations from 
pharmacies, hospitalizations, and ambulatory physician visits. Record linkage of 
these files enables to create person-based longitudinal files for a specific research 
question. Some databases such as the Canadian Saskatchewan’s Health Databases 
allow record linkage with cancer registries and thus the study of potential carcinogen 
drug effects. Other examples of administrative databases include the US Group 
Health Cooperative databases, the Kaiser Permanente databases, or the Medicaid 
databases.3 
Physician-based databases have been developed by researchers and consist of data 
entered by general practitioners (GPs) into their practice computers.3,11 The best 
known example is the United Kingdom (UK) General Practice Research Database 
(GPRD). The GPRD was started in June 1987 under the name Value Added Medical 
Products (VAMP) research databank. At that time, VAMP provided GPs with practice 
computers and the corresponding software with the idea to gradually replace the 
written medical record. In return, GPs agreed to undertake a training in standardized 
data entry and to provide anonymized patient data to a central database for 
subsequent use in public health research. During the 1990, VAMP research 
databank underwent several organizational and management changes. In 1994 the 
database was donated to the UK Department  of Health and  renamed GPRD.3,12 
INTRODUCTION  PHARMACOEPIDEMIOLOGY 
20 
Very recently, in April 2012 the GPRD has been transferred into the Clinical Practice 
Research Datalink (CPRD), the new English National Health Service (NHS) 
observational data and interventional research service, jointly funded by the NHS 
National Institute for Health Research (NIHR) and the Medicines and Healthcare 
products Regulatory Agency (MHRA).13 A more detailed description of the 
characteristics of the GPRD is found in the methods section of the studies in this 
thesis. Other examples of physician-based databases include The Health 
Improvement Network (THIN) database, which also uses medical records from UK 
patients, or the Intercontinental Marketing Services (IMS) Disease Analyzer 
(previously known as MediPlus) databases, which contains patient records from the 
UK, Germany, and France.14 
 
1.1.3 Study designs 
Case-control studies 
Case-control studies start with the outcome (e.g. the disease) and look backward in 
time for exposures that might have caused the outcome. The investigator defines a 
group of patients with a certain outcome of interest (e.g. myocardial infarction) (the 
cases) and another group of patients without the outcome (the controls). Then, 
through medical record review, interviews, or other means, the investigator compares 
the prevalence of a certain condition (e.g. hypertension) or the exposure to a certain 
drug (e.g. statins) between cases and controls and calculates a measure of 
association, the odds ratio (OR). If the OR is greater than 1, then the exposure 
represents a risk factor for the outcome, conversely if the OR is lower than 1, then 
the exposure is regarded as a protective factor. An OR of 1 signifies that the 
exposure is equally distributed between cases and controls. Case-control studies are 
especially useful for rare outcomes (e.g. autism) or outcomes that take a long time to 
develop (e.g. cancer). Such studies usually require less time, effort, and money than 
would cohort studies. On the other hand, a major concern in case-control studies is 
the choice of an appropriate control group. Controls should be similar to cases in all 
important respects except for not having the outcome of interest.15,16  
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Cohort studies 
Cohort studies proceed in a logical sequence: from exposure to outcome. In cohort 
studies the investigator identifies two groups: one with the exposure of interest (e.g. 
use of antipsychotics) and another one without. He then follows both groups forward 
in time to determine the outcome of interest (e.g. stroke). If the exposed group 
develops a higher incidence of the outcome than the unexposed group, then the 
exposure is associated with an increased risk, otherwise the exposure has protective 
properties.16,17 There are two types of cohort studies: prospective and retrospective 
ones. In prospective cohort studies the investigators assesses the exposure at 
baseline and follows individuals forward in time to study the outcome of interest, as 
described above. In retrospective cohort studies the investigator starts the study at 
the time follow-up has already been completed. Retrospectively, eligible individuals 
are identified, the cohort is composed and exposure is assessed at baseline. 
Subsequently, occurrence of outcome is studied during the historical observational 
period.18 Cohort studies are useful to study rare exposures. Another advantage is 
that they allow investigating multiple outcomes after a single exposure (e.g. cigarette 
smoking and the development of chronic obstructive pulmonary disease (COPD), 
lung cancer, or ischemic heart disease). On the other hand, cohort studies have also 
limitations. Differential losses of follow-up between exposed and unexposed 
individuals can bias results. Another problem (particularly with longitudinal studies 
that continue for decades) is that exposure status of study individuals may change 
over time (e.g. switch to another antihypertensive agent).17,19 
 
Nested case-control studies 
The nested case-control study is a relatively new study design and can basically be 
regarded as a case-control study within a cohort study. It starts analogously to a 
cohort study with a defined cohort of individuals that is followed forward in time to 
study the occurrence of a certain outcome. But instead of analyzing person-time data 
for everyone in the cohort (as done in the classic cohort study) the analysis is 
conducted as a case-control study, where for each case (i.e. each individual who 
developed the outcome), a defined number of controls (i.e. individuals who did not 
develop the outcome during follow-up) is selected from the initial cohort. The number 
of selected controls per case is usually 4, but occasionally may go up to 10. Nested 
case-control studies have several advantages compared to classical cohort studies. 
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First, they allow better control for potential confounders (cf. chapter 1.1.4) such as 
age, calendar time or disease duration through matching. Second, they are less 
expensive to perform and the collection and analysis of data are less time-consuming 
Third, they allow better quantification of drug exposure with respect to time. This is 
important because the traditional (time-independent) Cox proportional hazard model 
(which is commonly used for the analysis of data from cohort studies) does not 
account for the time-dependent nature of drug use over time. 20,21  
 
Other study designs 
Other, more recent study designs include the case-crossover and the case-time-
control design. They are particularly useful for studying intermittent drug exposures 
with transient effects and are less susceptible to confounding by indication (cf. 
chapter 1.1.4). In case-crossover studies the exposure history of each case is used 
as his or her own control. Hence, cases and controls are comparable in most of their 
known and unknown confounders except for intermittent exposures. This eliminates 
the problem of between-person confounding by constant characteristics. The case-
time-control design is a refinement of the case-crossover design. It uses exposure 
history from a conventional control group to estimate and adjust for the bias from 
temporal changes in prescribing.22  
 
1.1.4 Bias 
Bias in epidemiology refers to a systematic error which results in an incorrect 
estimate of the measure of association. Roughly, three broad categories of bias can 
be distinguished: selection bias, information bias, and confounding. 
 
Selection bias 
Selection bias is a systematic error that derives from procedures used to select 
subjects and from factors that influence study participation. It comes about when the 
association between exposure and outcome differs for those who are and those who 
are not included in the study. As the association between exposure and outcome 
among those who are not included in the study is usually unknown, the presence of 
selection bias must usually be inferred, rather than observed.23 One example of 
selection bias is the ‘healthcare access bias’. This type of bias is introduced when 
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patients admitted to an institution do not represent the cases originated in the 
community. This may occur when a healthcare organization is organized in 
increasing levels of complexity (e.g. primary, secondary, and tertiary care) and 
complex cases are automatically referred to tertiary care or when patients by cultural, 
geographical, or economic reasons show a differential degree of access to an 
institution.24 Another example of selection bias is the ‘detection bias’. This type of 
bias is introduced when a specific outcome is diagnosed preferentially in individuals 
who are exposed to the drug that may be associated with that outcome.25 
 
Information bias 
An information bias in a study can arise when the information collected from study 
subjects is erroneous. If a variable (e.g. the exposure) is measured on a categorical 
scale and the error leads to a patient placed in a wrong category, then this 
information if often referred to as being misclassified. Misclassification of study 
subjects can be differential or non-differential. Differential misclassification bias is 
present when misclassification is different in the groups to be compared. 
Alternatively, non-differential misclassification bias is present when the 
misclassification is the same across the groups to be compared, for example, 
exposure is equally misclassified in cases and controls.23-25 A common type of 
information bias is ‘recall bias’. This type of bias occurs in case-control studies where 
a subject is interviewed to obtain exposure information after the outcome has 
occurred. For example in a case-control study that aims at studying the influence of 
different exposures during pregnancy on the risk of developing a birth defect, 
mothers of babies with a birth defect (cases) may be more likely to recall their 
exposure histories than mothers with a healthy baby (controls) because the birth 
defect serves as a stimulus for the mother to consider potential causes.23 Another 
type of information bias is ‘protopathic bias’. This type of bias occurs when a drug is 
inadvertently prescribed for an early manifestation of a disease that has not yet been 
diagnosed. When the disease is later discovered, a causal association between the 
drug and the disease may be incorrectly inferred. As an example, in a case-control 
study of estrogens and endometrial cancer, about 10% of the women exposed to 
estrogens specifically stated that the oral estrogen had been prescribed by their 
physician to treat an episode of uterine bleeding.26  
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Confounding 
Confounding is a central issue for epidemiologic studies. Basically, confounding can 
be thought of as a mixing of effects. A confounding variable must have an effect and 
must be imbalanced between the exposure groups to be compared. In order for a 
variable to be considered as a confounder, it must meet three specific criteria: (1) it 
has to be associated with the outcome (either as a cause or a proxy for a cause but 
not as an effect of the outcome), (2) it has to be associated with the exposure and (3) 
it must not be an effect of the exposure.23,25 As an example, a study in the 1960s 
showed a remarkable trend in prevalence of Down’s syndrome with increasing birth 
order.27 However, a third variable – the mother’s age – was not taken into account. 
Mother’s age is a confounding factor in so far as children with higher birth order tend 
to be born to older mothers and higher maternal age is an independent risk factor for 
Down’s syndrome.23 Confounding can be prevented at the design stage of a study by 
matching cases and controls on a potential confounding variable (in case-control 
studies), restriction of the study population to subjects who might have the same or 
nearly the same value for a potential confounder, or randomization, i.e. the random 
assignment of study subjects to experimental groups (in randomized controlled trials). 
In the analysis confounding can be controlled for by stratifying results at the level of 
the potential confounder or by performing multivariate analysis.23,24 A particular type 
of confounding bias is ‘confounding by indication’. This type of confounding bias is 
present if the indication for the prescription of a drug under study is also a 
determinant of the outcome of interest. Generally, a drug is more likely to be 
prescribed to a patient with more severe disease who, in turn, is more likely to 
experience an adverse outcome of the disease. Thus, patients prescribed the drug 
under study will have higher incidence rates of the outcome than those not 
prescribed the drug. This could simply be a reflection of the effect of disease severity, 
rather than of the drug itself.3 As an example, in the study of the association between 
cimetidine and gastric cancer, the indication peptic ulcer is regarded as the potential 
confounder.28
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1.2 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder and 
one of the most disabling and burdensome health conditions worldwide. It is the most 
common form of dementia, accounting for about 60–80% of all cases.29 The disease, 
which was firstly described by the German pathologist Alois Alzheimer more than 100 
years ago (in 1906), is clinically characterized by a gradual decline in cognitive 
function, the presence of psychiatric symptoms, and increasing difficulties in 
performing activities of daily living (ADL).30 
 
1.2.1 Epidemiology 
In 2006, the number of people affected by AD was 26.6 million worldwide. By 2050 
this number is expected to increase fourfold to 106.8 million.31 China and its 
developing western-Pacific neighbors have the highest numbers of affected 
individuals, followed by western Europe, and North America.32 In the United States 
approximately 13% of those aged ≥65 years have AD and it is estimated that every 
68 seconds a new case is added. By 2050, there’s expected to be one new case 
every 33 seconds, or almost 1 million new cases per year.29 Generally, there are 
more women with AD than men. This is mainly explained by the fact, that women live 
on average longer than men.33 The incidence of AD increases dramatically with 
increasing age and doesn’t seem to level off after the age of 90.34 In Switzerland, 
107,000 people had a diagnosis of AD or another dementia form in 2010. It is 
estimated that this number will increase to approximately 200,000 by 2030 and 
300,000 by 2050.35 
 
1.2.2 Pathogenesis 
The two core pathological hallmarks of AD are plaques, composed of  β-amyloid (Aβ) 
peptides and neurofibrillary tangles, composed of hyperphosphorylated tau protein. 
Aβ peptides are natural products of metabolism consisting of 36–43 amino acids. 
They originate from proteolysis of the amyloid precursor protein (APP) by the 
sequential enzymatic actions of β-site APP-cleaving enzyme 1 (BACE-1), a β-
secretase, and γ-secretase, a protein complex with presenilin 1 at its catalytic core. 
The so-called ‘amyloid cascade hypothesis’ suggests that an imbalance between 
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production and clearance, and aggregation of peptides causes Aβ to accumulate and 
this excess may be the initiating factor of synaptic dysfunction and neuronal cell 
death in AD.36,37 Originally, only plaques and amyloid-fibrils were thought to cause 
toxicity, but recent research has shown that soluble oligomers (2–6 peptides) and 
intermediate amyloids (assemblies of coalesced peptides) are the most neurotoxic 
forms of Aβ.38 The major constituent of neurofibrillary tangles is an abnormally 
hyperphosphorylated and aggregated form of tau. Tau is an abundant soluble protein 
in axons that promotes assembly and stability of microtubules and vesicle transport. 
Hyperphosphorylated tau is insoluble and aggregates into paired helical filament 
structures, the neurofibrillary tangles. Additionally, hyperphosphorylated tau 
destabilizes microtubule structure. Both procedures lead to impaired axonal transport 
and thus disruption of structure and function of neurons.36,37 Similarly to Aβ 
oligomers, intermediate aggregates of hyperphosphorylated tau are cytotoxic and 
impair cognition.37,39,40 The number of neurofibrillary tangles is a pathologic marker of 
the severity of AD.37 Evidence from in-vitro studies suggests that Aβ accumulation 
triggers tau aggregation.41,42 
 
1.2.3 Diagnosis 
A definite diagnosis of AD can only be made post-mortem. Clinically, only a probable 
diagnosis is possible at present. For a clinical diagnosis of AD a detailed history of 
the symptoms is taken (either from the patient, partner or caregiver), and a clinical, 
neurological, and psychiatric examination is performed. Laboratory studies, such as 
thyroid-function tests, serum vitamin B12, or folate levels are recommended to identify 
secondary causes of dementia or common co-existing disorders. Neuroimaging plays 
an important role in the diagnosis of AD. Computed tomography (CT) or magnet 
resonance imaging (MRI) are useful to detect intracranial lesions or to exclude 
alternative causes of dementia (e.g. brain tumor or subdural hematoma). 
Neuroimaging is also helpful to measure cerebral atrophy or to detect 
cerebrovascular disease (e.g. cerebral infarcts or white matter lesions).30,36,43 The 
clinical diagnosis of AD is made according to the National Institute of Neurological 
and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease 
and Related Disorders Association (ADRDA) criteria.44 Recently, the National 
Institute on Aging (NIA) and the Alzheimer's Association released updated diagnostic 
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criteria for AD.45 These new criteria establish that AD exists on a continuum and 
encompasses not only dementia but also a preclinical phase and a phase of mild 
cognitive impairment due to AD.46 Additionally, these new criteria promote the 
incorporation of biomarkers into routine diagnosis of AD. The major AD biomarkers 
that have been widely investigated include (1) biomarkers of brain Aβ protein 
deposition:  low cerebrospinal fluid (CSF) Aβ42 and positive positron emission 
tomography (PET) amyloid imaging; (2) biomarkers of downstream neuronal 
degeneration or injury: elevated CSF tau (both total tau and phosphorylated tau), 
decreased 18fluorodeoxyglucose (FDG) uptake on PET in tempo-parietal cortex, and 
disproportionate atrophy on structural magnetic resonance imaging in medial, basal, 
and lateral temporal lobe, and medial parietal cortex.45 
 
1.2.4 Treatment 
At present, no curative treatment for AD exists. Currently available treatment options 
– acetylcholinesterase inhibitors (AChEI) and memantine – are symptomatic and do 
not halt or reverse disease progression. Tacrine was the first AChEI approved for 
treatment of AD in 1993, but due to the risk of serious hepatotoxicity and 
controversial efficacy it is rarely used in practice now.47 The other AChEIs donepezil, 
rivastigmine and galantamine are licensed for the treatment of mild to moderate AD 
and constitute the mainstay of drug therapy in AD. AChEIs delay the degradation of 
acetylcholine released into the synaptic cleft and so enhance cholinergic 
neurotransmission. The efficacy of these drugs has been studied in more than 30 
placebo-controlled randomized clinical trials (RCTs). Most trials had a duration of six 
months and included patients with mild to moderate disease (mini-mental state 
examination [MMSE] score of 10–26). Results were a modest positive effects on 
cognition (1.5–2 points on the MMSE over 6–12 months), with additional short-term 
(3–6 months) improvement in global outcome and stabilization of function over this 
period.36 There’s no evidence that these drugs differ in efficacy.48 Memantine is an N-
methyl-D-aspartate (NMDA)-receptor antagonist, which is licensed for the treatment 
of moderate to severe AD. It is believed to modulate the effects of pathologically 
elevated levels of glutamate that may lead to neuronal dysfunction. A pooled analysis 
of three RCTs showed modest positive effects on cognitive and behavioral symptoms 
and improved ADLs at six months in patients with moderate to severe AD.49 Studies 
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comparing AChEI monotherapy with the combination of  memantine and AChEIs 
showed that the combination is superior in slowing the progression of cognitive and 
functional decline50 and delaying time to nursing home admission.51 Behavioral signs, 
such as aggression, agitation, and psychosis (hallucinations and delusions) in 
patients with dementia are commonly treated with antipsychotic drugs, but benefits 
are moderate, and serious adverse events include sedation, parkinsonism, chest 
infections, ankle edema, and an increased risk of stroke and death.36 Additionally, 
recent research suggests that use of antidepressant drugs to treat co-morbid 
depression in patients with AD may provide little benefit but increase the risk of drug-
related adverse events.52 
 
1.2.5 Risk and protective factors 
Several risk factors have been linked to the development of AD, though with partially 
weak or controversial evidence. Well established risk factors are advancing age 
(which is certainly the most important one) and genetics (cf. chapter 1.2.6). Other 
potential risk factors include a history of head injury,53 depression,54 a low cognitive 
reserve (which depends on education, occupation, and mental activities),55 low 
physical activity and exercise,56 midlife obesity,57 alcohol consumption,58 and 
smoking.59 Additionally, a number of cardiovascular (CV) diseases such as atrial 
fibrillation,60 heart failure,61 stroke,62 midlife hypertension,63 midlife 
hypercholesterolemia,64 and diabetes mellitus (DM)65 have also been associated with 
an increased risk of developing AD. On the other hand, there’s some evidence that 
supplementary intake of vitamin B12 and folate,66 antioxidants such as vitamin C and 
E,67 ω-3 fatty acids,68 or moderate wine consumption,69 could reduce the risk of 
developing AD, but data so far are not conclusive to make any general 
recommendations. However, it has been shown that a Mediterranean diet has the 
potential to reduce the risk of AD.70 Additionally, certain drugs such as non-steroidal 
anti-inflammatory drugs (NSAIDs), statins or estrogens (hormone replacement 
therapy) have been associated with a reduced risk of developing AD in observational 
studies but failed to show any benefit in large RCTs.43 However, there’s some 
promising evidence that certain anti-hypertensive drugs such as angiotensin (AT)-II 
receptor antagonists could lower the risk of developing AD.71 
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1.2.6 Genetics 
Genetics play an important role as risk factors in both, early-onset (or familial) AD, 
which is characterized by a disease onset before the age of 65 years, and late-onset 
(or sporadic) AD with a disease onset after the age of 65 years. Early-onset AD is an 
autosomal dominant disorder. It is caused by mutations in three genes: the APP, 
presenilin 1, and presenilin 2 on chromosomes 21, 14 and 1, respectively.30 
However, early-onset AD accounts for less than 5% of all AD cases.72 For late-onset 
AD, the only known genetic risk factor is apolipoprotein E (ApoE), located on 
chromosome 19. ApoE acts as a cholesterol transport protein in the brain. Three 
gene forms exist (ApoE ε2, Apoe E ε3, and Apo E ε4).30,43 Homozygous carriers of 
the ε4 allele have a threefold increased risk of developing late-onset AD, 
heterozygous carriers a 15-fold.73  
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1.3 VASCULAR DEMENTIA 
Vascular dementia (VD) is the second most common form of dementia in the elderly 
after AD, accounting for about 10–20% of all dementia cases.74,75 Similarly to AD, the 
prevalence of VD increases continuously with increasing age and affects about 1.6% 
of those aged 65 years or more in Europe.75 As the name implies the common cause 
of VD is the CVD lesion resulting from vascular and circulatory pathology. The 
primary lesions of VD are intracerebral hemorrhage, intracerebral ischemia, and 
combinations thereof. The ischemic forms of VD are generally divided into ‘large-
vessel’ and ‘small-vessel’ disease, although some degree of overlap usually exists. 
Large vessel disease results from repeated strokes leading to multi-infarct dementia, 
or to a single strategic cortico-subcortical stroke affecting mainly anterior or posterior 
cerebral artery territories. Small vessel disease affects the small vessels of the brain 
and causes both lacunar strokes and Binswanger disease. The latter is characterized 
by incomplete ischemia of the periventricular white matter.76,77 The clinical diagnosis 
of VD is made according to the National Institute of Neurological Disorders and 
Stroke (NINDS) and the Association Internationale pour la Recherche et 
l'Enseignement en Neurosciences (AIREN) criteria.78 According to these criteria, 
three elements are required: (1) cognitive loss, (2) presence of cerebrovascular 
lesions as shown by brain imaging (or as inferred from a history of stroke and 
presence of focal neurological signs), and (3) onset of dementia within three months 
of a symptomatic stroke. (The latter condition does not apply for patients with 
subacute VD). Additionally, other causes of dementia such as AD must be excluded 
(although AD and VD often coexist79).77 So far, no drug has been approved for the 
treatment of VD. However, AChEIs80-82 and memantine83 have been studied in 
patients with VD. Although these drugs were shown to produce some benefit on 
cognition, the effect size was rather small and of uncertain clinical significance.84 
Prevention strategies for VD should focus on the prevention of stroke and CV 
diseases with attention to control of risk factors such as hypertension, DM, 
hypercholesterolemia, and hyperhomocysteinemia.77 Promising results have so far 
been demonstrated with the calcium channel blocker nitrendipine,85 angiotensin 
converting enzyme (ACE) inhibitiors, and diuretics.86 Additionally, AT-II receptor 
antagonists may be particularly effective because of their additional anti-ischemic 
effects in the brain.87,88 
  
 
 
CHAPTER 2 
 
 
AIMS OF THE THESIS 
  
AIMS OF THE THESIS 
33 
2 AIMS OF THE THESIS 
The overall aim of this thesis was to contribute to the understanding of the natural 
history of the two most common dementia subtypes AD and VD, by using data from 
the GPRD, a large and well-established physician-based primary care database from 
the UK.  
The aim of the first study (3.1) was to provide new data on the incidence of AD and 
VD in the UK and quantify the prevalence of co-morbidities and drugs used prior to 
the time of diagnosis. Current UK estimates of the incidence of AD or VD are based 
on diagnostic limitations of the 1990s and there’s conflicting evidence on whether 
patients with AD or VD have more or less co-morbidities than non-demented 
individuals. Moreover, little is known about differences in drug use between patients 
with AD or VD and patients without dementia. 
In the second study (3.2) we aimed at investigating the influence of the antidiabetic 
drug metformin on the risk of developing AD. Recent data from in vitro and animal 
studies suggest that this drug ameliorates typical AD pathology and thus could have 
a protective effect on the development of AD. 
In the third and fourth study we followed patients with AD or VD forward in time to 
see whether they developed more or less often a certain disease (complication) of 
interest than patients without dementia. The diseases of interest in this case were 
seizures/epilepsy in Study 3.3 and ischemic stroke, hemorrhagic stroke or transient 
ischemic attack (TIA) in Study 3.4 Additionally, we aimed at studying the role of 
potential risk factors on the risk of developing such a disease of interest, in particular 
the role of anti-dementia drugs on the risk of seizures or epilepsy (Study 3.3) and the 
role of antipsychotic drugs on the risk of ischemic stroke, hemorrhagic stroke or TIA 
(Study 3.4). For both drugs there’s limited or conflicting evidence from the literature 
on whether they increase the risk of the corresponding diseases or not. 
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3.1.1 Abstract 
Background: Epidemiologic studies on age-specific incidence rates (IRs) separating 
Alzheimer’s disease (AD) and vascular dementia (VD) in the UK are scarce. We 
sought to assess IRs of AD and VD in the UK and to compare co-morbidities and 
drug use between patients with AD, VD, or without dementia.  
 
Methods: We identified cases aged ≥65 years with an incident diagnosis of AD or VD 
between 1998 and 2008 using the General Practice Research Database (GPRD). We 
assessed IRs, stratified by age and sex, matched one dementia-free control patient 
to each demented patient, and analyzed co-morbidities and drug use. 
 
Results: We identified 7,086 AD and 4,438 VD cases. Overall, the IR of AD was 
1.59/1,000 person-years (py) (95% CI 1.55–1.62) and the IR of VD 0.99/1,000 py 
(95% CI 0.96–1.02). For AD, IRs were higher for women than for men, but not for VD. 
Except for orthostatic hypotension, the prevalence of all cardiovascular (CV) co-
morbidities and exposure to CV drugs was lower in patients with AD than in 
corresponding controls, whereas the opposite was true for VD.  
 
Conclusions: The prevalence of CV diseases was lower in patients with AD. This may 
be a true finding or the result of diagnostic bias, i.e. demented patients with CV 
diseases may be more likely to be diagnosed with VD than AD. 
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3.1.2 Introduction 
Dementia is one of the main causes of disability in elderly people.89 In the UK, 
currently more than 820,000 people (about 1.3% of the population) have dementia, 
and that this number is estimated to increase to over 1,735,000 by the year 2051.90,91 
Dementia poses a heavy socioeconomic burden, generating annual costs of more 
than £23 billion in the UK.91 The MRC CFA Study, a large population-based study 
assessing the prevalence and incidence of dementia in the UK, estimated some 
180,000 new dementia cases in England and Wales each year.92 However, UK data 
on the incidence of the most common subtypes of dementia, i.e. Alzheimer’s disease 
(AD) and vascular dementia (VD), are based on only a few small studies from the 90s 
with little statistical power and diagnostic limitations of that time.93,94 
Many older patients – whether demented or not – suffer from co-morbidities. Previous 
studies observed that patients with AD had generally less co-morbidities than non-
demented patients, and it was suggested that patients with AD represent the 
healthiest group of demented patients.95,96 More recent studies, however, reported 
significantly higher prevalence rates of co-morbidities for patients with AD.97,98 
Moreover, comparison of drug use between demented and non-demented patients 
revealed that demented patients use more central nervous system (CNS) active 
drugs, but fewer cardiovascular drugs than non-demented patients.99 However, little 
is known about differences in drug use between patients with AD or VD and those 
without dementia. 
We assessed incidence rates of AD and VD in the UK using primary care data, and 
we compared the prevalence of co-morbidities and drug use between patients with 
AD or VD and a comparison group without dementia.  
 
3.1.3 Methods 
Data source 
We used the UK-based General Practice Research Database (GPRD) which was 
established in around 1987 and encompasses data on some 11 million patients who 
are or were registered with selected general practitioners (GPs).100 The patients 
enrolled in the GPRD are representative of the UK population with regard to age, sex, 
geographic distribution, and annual turnover rate. The GPs have been trained to 
record medical information for research purposes in a standardized manner. The 
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information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, and hospitalizations. Since the doctors generate drug prescriptions 
directly with the computer using a coded drug dictionary, all recorded prescriptions 
include the name of the preparation, route of administration, dose of a single unit, 
number of units prescribed and, in most instances, intake regimen. The database has 
been described in detail elsewhere101,102 and validated extensively.103,104 
The study was approved by ISAC, the Independent Scientific Advisory Committee for 
Medicines and Healthcare products Regulatory Agency (MHRA) database research. 
 
Case selection and validation 
Based on Read codes, we identified patients aged ≥ 65 years with a first-time 
diagnosis of AD, VD, or any unspecified dementia recorded between January 1998 
and September 2008, or who received a first-time prescription for an 
acetylcholinesterase inhibitor (i.e. donepezil, rivastigmine, galantamine, or tacrine) or 
the N-methyl-D-aspartate (NMDA)-receptor antagonist memantine, i.e. two 
treatments mainly used for AD. The date of the first-time diagnosis or the first-time 
prescription for one of the above-mentioned drugs, whichever came first, will 
subsequently be referred to as ‘index date’. Patients with less than three years of 
active history in the database prior to the index date and those with a history of 
HIV/AIDS, alcoholism, drug abuse, multiple sclerosis, motor neuron disease, or 
Down’s syndrome prior to the index date were excluded.  
Since we intended to differentiate between the dementia subtypes AD and VD, we 
aimed at increasing the probability of including only well-defined cases of each 
subtype in the study population. We therefore manually reviewed 500 patient profiles 
and developed an algorithm which we applied to all potential AD, VD or unspecified 
dementia cases. To be included as an eligible AD case, a patient was required to 
have either (1) a diagnosis of AD followed by at least one prescription for an AD drug 
or vice versa, (2) a diagnosis of unspecific dementia followed by at least two 
prescriptions for an AD drug, (3) at least two recordings of an AD diagnosis, (4) an 
AD diagnosis after a specific dementia test (e.g. Mini Mental State Examination 
[MMSE], Clock Drawing Test [CDT], or Abbreviated Mental Test [7-Minute Screen]), 
a referral to a specialist (e.g. neurologist, geriatrician or psycho-geriatrician), or an 
assessment based on neuro-imaging technique (e.g. magnet resonance imaging 
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[MRI], computed tomography [CT], or single photon emission CT SPECT]), or (5) an 
AD diagnosis preceded or followed by any recorded dementia symptoms (e.g. 
memory impairment, aphasia, apraxia, or agnosia). In addition, cases with a 
recording of any other specific dementia diagnosis (e.g. VD, Pick’s disease, or Lewy 
body dementia [LBD]) after the index date were not eligible, as well as those with a 
stroke diagnosis within two years prior to the index date. According to the NINDS-
AIREN criteria78 for the diagnosis of VD, patients who develop signs of dementia 
within three months following stroke are likely to have VD. However, as the diagnosis 
of VD in the UK is made by specialists, GPs often get this information with delay and 
therefore time of recording in the GPRD is often not consistent with the actual time of 
diagnosis; thus, we decided to expand our time window to two years. Analogously, to 
be included as an eligible VD case, a patient was required to have either (1) a 
diagnosis of VD or unspecified dementia within two years after a stroke, (2) at least 
two recordings of a VD diagnosis, (3) a VD diagnosis after a specific dementia test, a 
referral to a specialist, or an assessment based on neuro-imaging technique, or (4) a 
VD diagnosis preceded or followed by any recorded dementia symptoms. In addition, 
cases with a recording of any other subtype dementia diagnosis (e.g. AD, Pick’s 
disease, or LBD) or a prescription of a specific drug to treat AD after the index date 
were not eligible.  
This algorithm was a modified version of two case identification procedures from 
previous studies conducted using the GPRD.105,106 To validate the algorithm, we sent 
a questionnaire to GPs for a random sample of 60 AD and 60 VD cases to get 
additional information on the clinical circumstances and the diagnostic steps taken. A 
copy of this questionnaire is provided in the appendix. In 79% of the AD cases the 
GPs confirmed the recorded AD diagnosis, whereas in the other AD cases the 
diagnosed dementia subtype was either different, not further specified, or the case 
did not have confirmed dementia. For VD, the corresponding confirmation rate was 
74%.  
 
Incidence rates 
We estimated incidence rates (IRs) of AD and VD in the GPRD population for 
patients aged 65 years or more between January 1998 and September 2008, 
stratified by age (5-year age-groups) and sex. IRs were calculated as the number of 
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incident cases divided by the total number of persons-years (py) at risk with 95% 
confidence intervals (CIs).  
 
Controls 
From the base population we identified for each case with AD or VD one control 
patient without any type of dementia and without any prescription for a specific drug 
to treat AD at any time. Controls were matched to cases on age (same year of birth), 
sex, calendar time (same index date), GP, and number of years of recorded history in 
the database. We applied the same exclusion criteria to controls as to cases.  
 
Co-morbidities and drug use 
We assessed the prevalence of various co-morbidities recorded prior to the index 
date in cases with AD or VD as well as in the corresponding dementia-free controls. 
The co-morbidities of interest were congestive heart failure, atrial fibrillation, ischemic 
heart disease, hypertension, diabetes mellitus, hypercholesterolemia, orthostatic 
hypotension, chronic obstructive pulmonary disease (COPD), osteoporosis, 
inflammatory bowel disease, thyroid disorders, rheumatoid arthritis, 
epilepsy/seizures, and depression. We assessed the exposure to various drugs to 
treat these co-morbidities, whereby we focused on use during the last year prior to 
the index date.  
 
Statistical analysis 
We conducted conditional logistic regression analyses to compare co-morbidities and 
drug use between cases and controls using the statistical software SAS (version 9.2, 
SAS Institute Inc., Cary, NC, USA).  
 
3.1.4 Results 
Based on Read codes we identified 24,734 patients with a first-time diagnosis of AD, 
VD, unspecified dementia, or a first-time prescription for a drug used to treat AD. 
After applying the above described algorithm, a total of 7,086 AD cases (28.6%) and 
4,438 VD cases (17.9%) remained. The characteristics are displayed in Table 3.1-1. 
 
 
DEMENTIA PROJECT  EPIDEMIOLOGY, CO-MORBIDITIES AND DRUG USE 
43 
Incidence rates 
The IRs of AD were higher for women than for men across all age categories, most 
pronounced in the higher ages. By contrast, the IRs of VD were similar for men and 
women in all age categories, except for those aged 70–74 or 85–89 years, where it 
was (slightly) higher for men. Overall, the IR of AD was 1.59/1,000 py (95% CI 1.55–
1.62), and the IR of VD 0.99/1,000 py (95% CI 0.96–1.02). For both AD and VD, IRs 
increased with increasing age, with the highest age-specific IR for AD in those aged 
85–89 years (3.99/1,000 py, 95% CI 3.79–4.20) (Table 3.1-2).  
 
Co-morbidities and drug use 
Except for orthostatic hypotension, the prevalence of all cardiovascular (CV) co-
morbidities was lower in patients with AD than in the corresponding controls, whereas 
in patients with VD the contrary was observed. COPD and rheumatoid arthritis were 
also less prevalent among AD cases. Epilepsy/seizures or depression were both 
more prevalent among AD or VD cases than in corresponding controls, though the 
difference was more pronounced between patients with VD and their corresponding 
controls (Table 3.1-3).  
A similar observation was made regarding the exposure to various drugs to treat 
these co-morbidities. CV drugs were less commonly prescribed in patients with AD 
than in the corresponding controls, whereas in patients with VD – except for some 
drugs that were similarly frequently prescribed – the opposite was true. 
Corticosteroids were also less commonly prescribed in patients with AD. In patients 
with VD the exposure to CNS drugs was distinctively higher than in the 
corresponding controls, whereas in patients with AD this was particularly true for 
antidepressants and antipsychotics/neuroleptics (Table 3.1-4). 
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Table 3.1-1: Characteristics of patients with Alzheimer’s disease or vascular dementia and corresponding controls 
    
Alzheimer's disease 
  
Vascular dementia 
  
    
No. of cases (%) No. of controls (%) OR (95% CI) No. of cases (%) No. of controls (%) OR (95% CI) 
    
(n = 7086) (n = 7086)   (n = 4438) (n = 4438)   
Age [years] 
 
      65–69  410 (5.8) 411 (5.8) NA 157 (3.5) 156 (3.5) NA 
70–74 895 (12.6) 895 (12.6) NA 441 (9.9) 444 (10.0) NA 
75–79 1639 (23.1) 1638 (23.1) NA 882 (19.9) 880 (19.8) NA 
80–84 2029 (28.6) 2034 (28.7) NA 1254 (28.3) 1266 (28.5) NA 
85–90 1477 (20.8) 1475 (20.8) NA 1123 (25.3) 1114 (25.1) NA 
≥90 636 (9.0) 633 (8.9) NA 581 (13.1) 578 (13.0) NA 
        Sex 
 
        
Male 2198 (31.0) 2198 (31.0) NA 1801 (40.6) 1801 (40.6) NA 
Female 4888 (69.0) 4888 (69.0) NA 2637 (59.4) 2637 (59.4) NA 
  Smoking status 
 None 4182 (59.0) 4029 (56.9) 1.00 (Reference) 2370 (53.4) 2497 (56.3) 1.00 (Reference) 
Current  597 (8.4) 669 (9.4) 0.85 (0.76–0.96) 522 (11.8) 382 (8.6) 1.48 (1.28–1.72) 
Past 1626 (23.0) 1692 (23.9) 0.92 (0.84–1.00) 1145 (25.8) 1133 (25.5) 1.08 (0.97–1.20) 
Unknown 681 (9.6) 696 (9.8) 0.94 (0.82–1.07) 401 (9.0) 426 (9.6) 0.97 (0.82–1.16) 
 
BMI [kg/m2] 
 ≤18.4 308 (4.4) 162 (2.3) 1.49 (1.21–1.82) 197 (4.4) 107 (2.4) 1.65 (1.29–2.10) 
18.5–24.9 2907 (41.0) 2243 (31.7) 1.00 (Reference) 1663 (37.5) 1456 (32.8) 1.00 (Reference) 
25–29.9 1762 (24.9) 2189 (30.9) 0.61 (0.56–0.67) 1106 (24.9) 1356 (30.6) 0.70 (0.63–0.78) 
≥30 564 (8.0) 970 (13.7) 0.44 (0.39–0.50) 439 (9.9) 550 (12.4) 0.68 (0.59–0.79) 
Unknown 1545 (21.8) 1522 (21.5) 0.79 (0.72–0.87) 1033 (23.3) 969 (21.8) 0.96 (0.85–1.09) 
 
No. = Number; OR = Odds Ratio; CI = Confidence Interval; BMI = Body Mass Index; NA = Not Applicable 
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Table 3.1-2. Incidence rates of Alzheimer’s disease and vascular dementia (per 1,000 person-years), stratified by age (5-year age-groups) and sex 
    Alzheimer's disease  Vascular dementia 
           
 
Age-group 
[years] 
Person-
years at risk 
 
No. of 
Cases 
IR per 1,000 person-
years (95% CI) 
 
No. of 
Cases 
IR per 1,000 person-
years (95% CI) 
Men 65−69 558480  162 0.29 (0.25−0.34)  85 0.15 (0.12−0.19) 
 70−74 490707  346 0.71 (0.63−0.78)  244 0.50 (0.44−0.56) 
 75−79 393264  571 1.45 (1.34−1.58)  404 1.03 (0.93−1.13) 
 80−84 253286  587 2.32 (2.14−2.51)  494 1.95 (1.79−2.13) 
 85−89 120334  403 3.35 (3.04−3.69)  417 3.47 (3.15−3.81) 
 ≥90 45893  129 2.81 (2.37−3.34)  157 3.42 (2.93−4.00) 
 Total 1861964  2198 1.18 (1.13−1.23)  1801 0.97 (0.92−1.01) 
  
                  
Women 65−69 650962  248 0.38 (0.34−0.43)  72 0.11 (0.09−0.14) 
 70−74 606203  549 0.91 (0.83−0.98)  197 0.32 (0.28−0.37) 
 75−79 544593  1068 1.96 (1.85−2.08)  478 0.88 (0.80−0.96) 
 80−84 412040  1442 3.50 (3.32−3.68)  760 1.84 (1.72−1.98) 
 85−89 249801  1074 4.30 (4.05−4.56)  706 2.83 (2.63−3.04) 
 ≥90 140967  507 3.60 (3.30−3.92)  424 3.01 (2.74−3.31) 
 Total 2604566  4888 1.88 (1.82−1.93)  2637 1.01 (0.97−1.05) 
  
                  
All  65−69 1209441  410 0.34 (0.31−0.37)  157 0.13 (0.11−0.15) 
 70−74 1096909  895 0.82 (0.76−0.87)  441 0.40 (0.37−0.44) 
 75−79 937857  1639 1.75 (1.67−1.83)  882 0.94 (0.88−1.00) 
 80−84 665326  2029 3.05 (2.92−3.19)  1254 1.88 (1.78−1.99) 
 85−89 370136  1477 3.99 (3.79−4.20)  1123 3.03 (2.86−3.22) 
 ≥90 186860  636 3.40 (3.15−3.68)  581 3.11 (2.87−3.37) 
 Total 4466529  7086 1.59 (1.55−1.62)  4438 0.99 (0.96−1.02) 
  
                    
 
No. = Number; IR = Incidence Rate; CI = Confidence Interval 
DEMENTIA PROJECT             EPIDEMIOLOGY, CO-MORBIDITIES AND DRUG USE 
46 
Table 3.1-3: Prevalence of co-morbidities in patients with Alzheimer’s disease or vascular dementia and corresponding dementia-free controls 
    Alzheimer's disease   Vascular dementia 
                            
Co-morbidities  No. of Cases (%) No. of Controls (%) OR (95% CI)  No. of Cases (%) No. of Controls (%) OR (95% CI) 
   (n = 7086) (n = 7086)    (n =4438) (n =4438)   
Cardiovascular  
             
Congestive heart failure 448 (6.3) 677 (9.6) 0.63 (0.55–0.71)  600 (13.5) 465 (10.5) 1.35 (1.18–1.54) 
Atrial fibrillation 517 (7.3) 741 (10.5) 0.67 (0.60–0.76)  814 (18.3) 503 (11.3) 1.76 (1.56–1.99) 
Ischemic heart disease 1255 (17.7) 1630 (23.0) 0.72 (0.66–0.78)  1229 (27.7) 1099 (24.8) 1.17 (1.06–1.29) 
Hypertension 2627 (37.1) 3345 (47.2) 0.64 (0.60–0.69)  2299 (51.8) 2079 (46.9) 1.23 (1.13–1.34) 
Diabetes mellitus 570 (8.0) 747 (10.5) 0.75 (0.67–0.84)  655 (14.8) 474 (10.7) 1.45 (1.28–1.65) 
Hypercholesterolemia  643 (9.1) 726 (10.3) 0.86 (0.77–0.97)  453 (10.2) 419 (9.4) 1.11 (0.95–1.28) 
Orthostatic hypotension 206 (2.9) 131 (1.9) 1.59 (1.27–1.99)  198 (4.5) 105 (2.4) 1.96 (1.53–2.50) 
              
Inflammatory, endocrine, metabolic 
             
COPD 333 (4.7) 505 (7.1) 0.64 (0.55–0.73)  363 (8.2) 335 (7.6) 1.09 (0.93–1.27) 
Osteoporosis 657 (9.3) 660 (9.3) 1.00 (0.88–1.12)  397 (9.0) 375 (8.5) 1.07 (0.92–1.25) 
Inflammatory bowel disease 68 (1.0) 74 (1.0) 0.92 (0.66–1.28)  56 (1.3) 48 (1.1) 1.17 (0.79–1.73) 
Thyroid disorders  853 (12.0) 877 (12.4) 0.97 (0.87–1.07)  556 (12.5) 465 (10.5) 1.23 (1.08–1.41) 
Rheumatoid arthritis  159 (2.2) 199 (2.8) 0.79 (0.64–0.98)  105 (2.4) 108 (2.4) 0.97 (0.74–1.27) 
 
 
             
Central nervous system  
             
Epilepsy/seizures 144 (2.0) 112 (1.6) 1.29 (1.01–1.66)  215 (4.8) 84 (1.9) 2.62 (2.03–3.38) 
Depression 1527 (21.6) 1080 (15.2) 1.57 (1.43–1.71)  1121 (25.3) 636 (14.3) 2.13 (1.90–2.39) 
                              
 
No. = Number; OR = Odds Ratio; CI = Confidence Interval; COPD = Chronic Obstructive Pulmonary Disease 
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Table 3.1-4: Exposure prevalence to various drugs in patients with Alzheimer’s disease or vascular dementia and corresponding dementia-free controls 
    Alzheimer's disease   Vascular dementia 
                            
Drugs  No. of Cases (%) No. of Controls (%) OR (95% CI)  No. of Cases (%) No. of Controls (%) OR (95% CI) 
   (n = 7086) (n = 7086)    (n =4438) (n =4438)   
Cardiovascular  
             
ACE inhibitors 1057 (14.9) 1561 (22.0) 0.58 (0.53–0.63)  1142 (25.7) 961 (21.7) 1.31 (1.18–1.45) 
AT-II antagonists 261 (3.7) 547 (7.7) 0.44 (0.37–0.51)  307 (6.9) 330 (7.4) 0.92 (0.78–1.09) 
Beta-blocking agents 1213 (17.1) 1626 (23.0) 0.66 (0.61–0.72)  1012 (22.8) 949 (21.4) 1.16 (1.05–1.29) 
Calcium channel blockers 1121 (15.8) 1556 (22.0) 0.64 (0.58–0.70)  1085 (24.5) 1055 (23.8) 1.12 (1.01–1.24) 
Diuretics 2305 (32.5) 3242 (45.8) 0.51 (0.48–0.56)  2135 (48.1) 2021 (45.5) 1.28 (1.17–1.41) 
Vasodilators 727 (10.3) 1009 (14.2) 0.67 (0.61–0.75)  928 (20.9) 674 (15.2) 1.52 (1.36–1.70) 
Anti-arrhythmics 128 (1.8) 211 (3.0) 0.60 (0.48–0.75)  130 (2.9) 142 (3.2) 0.91 (0.71–1.16) 
Oral antidiabetics 344 (4.9) 413 (5.8) 0.82 (0.71–0.95)  404 (9.1) 297 (6.7) 1.42 (1.21–1.66) 
Insulin 72 (1.0) 122 (1.7) 0.59 (0.44–0.79)  122 (2.8) 75 (1.7) 1.64 (1.23–2.20) 
Statins 1200 (16.9) 1549 (21.9) 0.68 (0.62–0.75)  1241 (28.0) 902 (20.3) 1.69 (1.51–1.88) 
Antiplatelets 585 (8.3) 712 (10.1) 0.79 (0.71–0.89)  883 (19.9) 420 (9.5) 2.67 (2.33–3.05) 
Anticoagulants 252 (3.6) 390 (5.5) 0.62 (0.52–0.73)  395 (8.9) 276 (6.2) 1.51 (1.28–1.77) 
              
Inflammatory, endocrine, metabolic  
             
Antiosteoporotics 494 (7.0) 508 (7.2) 0.97 (0.85–1.10)  305 (6.9) 294 (6.6) 1.06 (0.89–1.26) 
Intestinal anti-inflammatory agents 51 (0.7) 64 (0.9) 0.79 (0.54–1.14)  44 (1.0) 29 (0.7) 1.51 (0.94–2.41) 
Corticosteroids 444 (6.3) 668 (9.4) 0.62 (0.55–0.70)  371 (8.4) 416 (9.4) 0.88 (0.76–1.03) 
NSAIDs 1257 (17.7) 1403 (19.8) 0.87 (0.79–0.96)  696 (15.7) 843 (19.0) 0.80 (0.71–0.91) 
Thyroid gland therapeutics 675 (9.5) 718 (10.1) 0.93 (0.83–1.04)  431 (9.7) 379 (8.5) 1.17 (1.01–1.35) 
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Table 3.1-4 cont. 
    Alzheimer's disease   Vascular dementia 
                            
Drugs  No. of Cases (%) No. of Controls (%) OR (95% CI)  No. of Cases (%) No. of Controls (%) OR (95% CI) 
   (n = 7086) (n = 7086)    (n =4438) (n =4438)   
Central nervous system   
             
Anticonvulsants 198 (2.8) 187 (2.6) 1.07 (0.87–1.31)  288 (6.5) 114 (2.6) 2.64 (2.11–3.29) 
Antidepressants 1793 (25.3) 958 (13.5) 2.26 (2.06–2.48)  1371 (30.9) 550 (12.4) 3.44 (3.05–3.88) 
Antipsychotics/neuroleptics 931 (13.1) 490 (6.9) 2.08 (1.85–2.34)  874 (19.7) 370 (8.3) 3.06 (2.66–3.52) 
Benzodiazepines 1047 (14.8) 968 (13.7) 1.13 (1.03–1.25)  886 (20.0) 602 (13.6) 1.72 (1.53–1.94) 
              
 
No. = Number; OR = Odds Ratio; CI = Confidence Interval; ACE = Angiotensin-Converting Enzyme; AT = Angiotensin; NSAIDs = Non-steroidal Anti-Inflammatory Drugs 
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3.1.5 Discussion 
In this large epidemiological study we estimated IRs of AD and VD in the UK 
population, stratified by age and sex. Our finding of a higher IR of AD in women than 
in men, particularly at higher age, is supported by other European studies also 
describing higher IRs of AD in women than in men.93,107-109 However, not all studies 
reported such a difference between men and women,110-112 and it has been proposed 
that the higher number of women with AD may be due to the longer life-expectancy of 
women rather than sex-specific characteristics of the disease.33 Regarding the sex-
specific IRs of VD, our finding of a similar rate in men and women is supported by a 
large pooled analysis of eight European studies that also found no substantial 
difference in sex-specific IRs of VD.74 Further support for our findings is given by 
another two European studies examining the effect of sex on the risk of developing 
VD and reporting no difference between men and women.107,109 By contrast, a higher 
risk of developing VD in men than in women was found in the Rotterdam study113 and 
in the Italian Longitudinal Study on Aging (ILSA).108 However, both studies were 
based on relatively few VD cases and IRs in the various age strata were not 
statistically significantly different.  
The increasing IR by age of both AD and VD in our study is consistent with findings 
of previous European studies.93,108-110 However, in comparison with those studies, 
our average IR estimates of AD were between three to six times lower. There are 
several possible reasons for this difference. The percentage of AD cases among all 
initially identified dementia cases in our study (AD, VD, or unspecified dementia) was 
quite low (28.6%) in comparison to the Girona Cohort study109 with 45.1% AD cases, 
the ILSA study108 with 52.7% AD cases, or the study of Barmejo-Pereja et al.110 with 
71.4 % AD cases. Since AD is the most common form of dementia, accounting for 
about 62% of all dementia cases in the UK90, a considerable proportion of the 
unspecified dementia cases in our study population may have been AD cases upon 
closer examination. However, in the MRC-ALPHA Study93, in which the percentage 
of identified AD (27.8%) and VD (12.2%) cases was similar to our study (28.6% and 
17.9%, respectively), the IR estimates of AD (4.9/1,000 py) and VD (2.6/1,000 py) 
were still about three times higher than ours (1.59/1,000 py and 0.99/1,000 py, 
respectively). This may be explained as follows: The MRC-ALPHA Study and the 
other above mentioned studies108-110 were prospective studies, i.e. each individual in 
the study population was actively screened for dementia at baseline and during 
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follow-up. This is in contrast to our study, in which any dementia diagnoses were 
diagnosed and recorded as part of daily recording routine of the GP in the absence of 
any study hypothesis. Notably, a recent UK study applied established dementia 
prevalence rates to UK population estimates and compared these figures to the 
number of diagnosed dementia cases reported by the GPs. This analysis revealed 
that almost 60% of all dementia cases in the UK go undiagnosed.114 Additionally, in 
our study dementia cases may not have been captured because elderly patients 
switch to nursing homes and may get lost from the GPRD. In this study we also 
compared the prevalence of co-morbidities between AD or VD cases and matched 
dementia-free controls. We found that, except for orthostatic hypotension, the 
prevalence of all cardiovascular co-morbidities was lower in patients with AD than in 
controls, whereas in patients with VD the opposite was true. A lower prevalence of 
cardiovascular co-morbidities in patients with AD as compared to non-demented 
patients was also observed in some previous studies.95,96  On the other hand there 
are studies reporting significantly higher prevalence rates of cardiovascular co-
morbidities in patients with AD than in dementia-free controls.97,98 Since certain 
cardiovascular co-morbidities such as hypertension,63 hypercholesterolemia,64 or 
DM65 are discussed as potential risk factors for AD, our finding of a lower prevalence 
of these disorders in patients with AD (as compared to dementia-free controls) may 
come as a surprise. However, this observation may be partially explained by 
diagnostic bias, i.e. the possibility that patients with a history of cardiovascular co-
morbidities may be more likely to be diagnosed with VD than AD.78 This notion is 
supported by the observation that the prevalence of cardiovascular co-morbidities 
was higher overall in patients with VD than in the dementia-free controls. Additionally, 
there is a possibility that certain diagnoses may be more likely to remain undetected 
in patients with dementia; in an elderly population of 1260 residents aged 64 years 
and above in Finland, patients with dementia had more undiagnosed 
hypercholesterolemia or hypothyroidism than non-demented controls.115 
We also assessed the exposure prevalence to various drugs and found that the 
exposure to all cardiovascular drugs was lower in patients with AD than in the 
dementia-free controls, whereas in patients with VD for most of these drugs the 
contrary was observed. Notably, evidence from recent epidemiological studies 
suggests that use of angiotension (AT) II receptor antagonists may reduce the risk of 
developing AD.71 However, since we observed a lower exposure prevalence to all 
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cardiovascular drugs in patients with AD than in the corresponding controls, and 
because these drugs are clearly linked to corresponding cardiovascular co-
morbidities above, the observed lower exposure prevalence to antihypertensive 
drugs may be biased, at least to some degree, and may not reflect a causal 
association. 
A limitation of our study is that the diagnosis of AD, VD, and other dementia types is 
not straightforward, and the recording of the diagnosis in a primary care record is by 
definition delayed, i.e. it does not occur until after a patient has had symptoms for a 
certain period of time prior to the actual recording date. Thus, as with many other 
slowly developing degenerative diseases, the disease onset (and therefore the index 
date) is not a precise point in time. This may affect some drug exposure estimates, 
particularly if early symptoms of the diseases of interest may affect the likelihood of 
beginning or stopping a given drug therapy prior to the actual index date. This can 
lead to spuriously low or high exposure estimates for drugs initiated or stopped within 
a few months prior to the recorded index date. Further, some degree of outcome 
misclassification is likely to occur as not all dementia diagnoses can be assigned to a 
certain subtype with certainty. It is, however, a strength of our study that we validated 
cases through use of a questionnaire and classified them by defining a sophisticated 
algorithm in the absence of any knowledge of the exposures of interest. The validity 
of this algorithm was corroborated by the fact that up to 80% of all our potential AD 
and up to 75% of all potential VD cases were confirmed by the GP using accepted 
diagnostic criteria for an AD or VD diagnosis. 
In summary, we identified patients with an incident diagnosis of dementia in a large 
population-based observational study, classified them into dementia subtypes, 
assessed IRs stratified by age and sex, and quantified the prevalence of co-
morbidities and drugs used prior to the index date. These data describe clinical 
characteristics of patients with an incident AD or VD diagnosis in a primary care 
setting in the UK. The risk estimates calculated to compare characteristics between 
patients with or without dementia are descriptive and are not intended to be 
interpreted as causal associations. Moreover, the relatively low IRs of AD and VD in 
this study indicate a certain degree of under-diagnosis of these disorders in the UK. 
  
DEMENTIA PROJECT  METFORMIN AND RISK OF ALZHEIMER’S DISEASE 
53 
 
 
 
3.2 METFORMIN, OTHER ANTIDIABETIC DRUGS AND RISK OF ALZHEIMER’S 
DISEASE: A POPULATION-BASED CASE-CONTROL STUDY 
 
 
 
Patrick Imfeld1,2, Michael Bodmer1, Susan S. Jick3, and Christoph R. Meier1,2,3 
 
 
 
 
1Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of 
Pharmaceutical Sciences, University of Basel, Basel, Switzerland 
2Hospital Pharmacy, University Hospital Basel, Basel, Switzerland 
3Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, 
MA, USA 
 
 
 
 
 
 
 
 
 
J Am Geriatr Soc 2012; 60(5):916-21 
 
DEMENTIA PROJECT          METFORMIN AND RISK OF ALZHEIMER’S DISEASE 
54 
3.2.1 Abstract 
Objectives: To explore the risk of developing Alzheimer’s disease (AD) in patients 
with diabetes mellitus treated with metformin or with other antidiabetic drugs. 
Design: Case-control study. 
Setting: The UK-based General Practice Research Database (GPRD), a well-
established primary care database.  
Participants: Seven thousand eighty-six cases aged 65 years or more with an 
incident diagnosis of AD identified between 1998 and 2008 and the same number of 
matched controls without dementia. Matching criteria were age, sex, general practice, 
calendar time, and years of history in the database. 
Measurements: Comparison of previous use of metformin or other antidiabetic drugs 
between cases and controls and calculation of corresponding odds ratios (ORs) with 
95% confidence intervals (CIs), using conditional logistic regression. Risk estimates 
were stratified by duration of use and adjusted for potential confounders. 
Results: As compared to non-users, long-term users of 60 or more metformin 
prescriptions were at an increased risk of developing AD (adj. OR 1.71, 95% CI 1.12–
2.60), but there was no consistent trend with increasing number of prescriptions. 
Long-term use of other antidiabetic drugs such as sulfonylureas (adj. OR 1.01, 95% 
CI 0.72–1.42), thiazolidinediones (adj. OR 0.87, 95% CI 0.31–2.40) or insulin (adj. 
OR 1.01, 95% CI 0.58–1.73) was not related to an altered risk of developing AD.  
Conclusions: Long-term use of sulfonylureas, thiazolidinediones, or insulin was not 
associated with an altered risk of developing AD. There was a suggestion of a slightly 
increased risk of AD in long-term users of metformin. 
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3.2.2 Introduction 
Evidence from epidemiological studies suggests that patients with diabetes mellitus 
are at increased risk of developing Alzheimer’s disease (AD),65,116-118 although not 
consistently in all studies.119-121 Studies on the association between antidiabetic 
medication and the risk of AD are scarce. In the Rotterdam study, diabetics treated 
with insulin had a substantially increased risk of developing AD.117 By contrast, a 
more recent neuropathologic study reported that patients treated with both insulin 
and oral antidiabetic drugs had a significantly lower neuritic plaque (NP) density than 
non-diabetic patients.122 
To our knowledge, data on metformin and the risk of AD only exist from in vitro 
studies or animal models. A recent study reported that metformin reduced 
phosphorylation of tau protein in cortical neurons of mice.123 Additionally, metformin 
was found to improve impaired neuronal insulin signaling and AD-related 
neuropathological changes in another recent in vitro study.124 These findings suggest 
that metformin may potentially play a role in reducing the risk of AD. However, the 
authors of another study found metformin to increase the generation of β-amyloid 
(Aβ) protein,125 indicating that its use may even promote the development of AD. 
The association between use of sulfonylureas or thiazolidinediones and the risk of 
developing AD has not been reported in published observational studies.  
We studied the association between diabetes and use of antidiabetic drugs, in 
particular metformin, and the risk of developing AD in a large population-based case-
control analysis.  
 
3.2.3 Methods 
Data source 
We used the UK-based General Practice Research Database (GPRD) which was 
established in around 1987 and encompasses data on some 11 million patients who 
are or were registered with selected general practitioners (GPs).100 The patients 
enrolled in the GPRD are representative of the UK population with regard to age, sex, 
geographic distribution, and annual turnover rate. The GPs have been trained to 
record medical information for research purposes in a standardized manner. The 
information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
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consultants, and hospitalizations. Since the doctors generate drug prescriptions 
directly with the computer using a coded drug dictionary, all recorded prescriptions 
include the name of the preparation, route of administration, dose of a single unit, 
number of units prescribed and, in most instances, intake regimen. The database has 
been described in detail elsewhere101,102 and validated extensively.103,104 
The study was approved by ISAC, the Independent Scientific Advisory Committee for 
Medicines and Healthcare products Regulatory Agency (MHRA) database research. 
 
Case selection and validation 
Based on Read codes, we identified patients aged 65 years or more who had a first-
time diagnosis of AD or any unspecified dementia recorded between January 1998 
and September 2008, or who received a first-time prescription for an 
acetylcholinesterase inhibitor (i.e. donepezil, rivastigmine, galantamine, or tacrine) or 
the N-methyl-D-aspartate (NMDA)-receptor antagonist memantine, i.e. two 
treatments specifically used for AD. The date of the first-time diagnosis or the first 
prescription to treat AD, whichever came first, will subsequently be referred to as 
‘index date’. Patients with less than three years of active history in the database prior 
to the index date, as well as those with a diagnosis of HIV/AIDS, alcoholism, drug 
abuse, multiple sclerosis, motor neuron disease, or Down’s syndrome prior to the 
index date were excluded. Since we intended to focus the study on AD, we aimed at 
increasing the probability of including only well-defined AD cases by conducting a 
manual review of 500 patient profiles, and developing an algorithm which we applied 
to all potential AD or dementia cases. To be included as an eligible AD case, a 
patient was required to have either (1) a diagnosis of AD followed by at least one 
prescription for an AD drug or vice versa, (2) a diagnosis of dementia followed by at 
least two prescriptions for an AD drug, (3) at least two recordings of an AD diagnosis, 
(4) an AD diagnosis after a specific dementia test (e.g. Mini Mental State 
Examination [MMSE], Clock Drawing Test [CDT], or Abbreviated Mental Test [7-
Minute Screen]), a referral to a specialist (e.g. neurologist, geriatrician or 
psychogeriatrician), a diagnostic test based on a neuroimaging technique (e.g. 
magnet resonance imaging [MRI], computed tomography [CT], or single-photon 
emission CT [SPECT]), or (5) an AD diagnosis preceded or followed by any recorded 
dementia symptoms (e.g. memory impairment, aphasia, apraxia, or agnosia). In 
addition, to reduce the likelihood of including patients with a dementia type other than 
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AD, cases were not eligible if they had a stroke prior to the index date (as this is more 
indicative of a diagnosis of vascular dementia [VD]78) or a recording of any other 
specific dementia diagnosis (e.g. VD, Pick’s disease, or Lewy body dementia) after 
the index date.  
This algorithm was a modified version of two case identification procedures of 
previous studies done on the GPRD.105,106 To validate the algorithm, we sent a 
questionnaire to GPs of a random sample of 60 AD cases to get additional 
information on the clinical circumstances and the diagnostic steps taken. A copy of 
this questionnaire is provided in the Appendix. The GPs of 79% of the AD case 
diagnoses confirmed the recorded AD diagnosis, whereas the other cases had either 
no dementia, were diagnosed with another dementia type, or the dementia type was 
not further specified.  
 
Controls 
From the base population we identified for each AD case one control patient without 
any evidence for any type of dementia and for any prescriptions for a specific drug to 
treat AD in their record at any time. Controls were matched to cases on age (same 
year of birth), sex, calendar time (same index date), GP, and number of years of 
recorded history in the database. We applied the same exclusion criteria to the 
controls as to the cases.  
 
Exposure to metformin or to other antidiabetics 
For both AD cases and dementia-free controls, we assessed exposure to metformin, 
sulfonylureas, thiazolidinediones, or insulin prior to the index date. We further 
categorized users of these drugs according to the number of recorded prescriptions 
prior to the index date (1–9, 10–29, 30–59, or ≥60 prescriptions for users of 
metformin, sulfonylureas, or insulin and 1–9, 10–29, or ≥30 prescriptions for users of 
thiazolidinediones. The exposure to other antidiabetic drugs (e.g. acarbose, glinides, 
gliptins, or exenatide) was not assessed due to the small numbers of users. Number 
of prescriptions is a proxy for exposure duration; an average prescription covers 45–
90 days of treatment depending on whether the patient was prescribed one or two 
tablets per day. 
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Statistical analysis 
We conducted conditional logistic regression analyses using the statistical software 
SAS, version 9.2 (SAS Institute, Inc., Cary, NC, USA). We calculated relative risk 
estimates as odds ratios (ORs) with 95% confidence intervals (CIs). For the main 
analyses we compared users of metformin, sulfonylureas, thiazolidinediones or 
insulin to non-users of the respective drugs. In a second model we categorized 
patients into mutually exclusive groups of users of metformin only, sulfonylureas only, 
insulin only, or thiazolidinediones only and assessed the risk of developing AD in 
comparison to patients without a diagnosis of diabetes mellitus. 
 
Covariates 
We controlled our analyses for the potential confounders age, sex, calendar time, 
GP,  and years of recorded history in the database by matching, and we adjusted for 
body mass index (BMI) (≤18.4, 18.5–24.9, 25–29.9, ≥30 kg/m2 or unknown) and 
smoking status (non, current, past, or unknown) in the multivariate model. For the 
main analyses (model 1) we adjusted the ORs for each antidiabetic drug for 
concomitant use of other antidiabetic drugs (metformin, sulfonylureas, 
thiazolidinediones, or insulin,). We did not control for acarbose, glinides, gliptins, or 
exenatide since exposure to these drugs was negligible. We further adjusted the ORs 
for a history of diagnosed hypertension or dyslipidemia, as well as for use of 
angiotensin converting enzyme (ACE) inhibitors or statins. Other potential 
confounders such as ischemic heart disease, heart failure, atrial fibrillation, 
depression, a history of head injury, use of angiotension (AT) II receptor antagonists, 
beta blockers, calcium channel blockers, diuretics, antiplatelets, anticoagulants, or 
non-steroidal anti-inflammatory drugs (NSAIDs) were also tested in multivariate 
analyses; however, as they had no material impact on the risk estimate for the 
association of interest, they were not included in the final model.  
 
3.2.4 Results 
We identified 20,753 cases with a first-time diagnosis of AD, dementia, or a first-time 
prescription for a drug used to treat AD. After applying the above described 
algorithm, a total of 7,086 AD cases and the same number of matched controls 
remained in the analysis. Table 3.2-1 displays the distribution of age and sex, 
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smoking status and body mass index (BMI), as well as the prevalence of 
hypertension and dyslipidemia in cases and controls. The mean age (± SD) of our 
study population at the index date was 80.7 (± 6.7) years and 69% were female. 
There were more underweight (BMI ≤18.4 kg/m2) AD cases than controls, while the 
opposite was true for overweight (BMI 25–29.9 kg/m2) or obese (BMI ≥30 kg/m2) 
patients (Table 3.2-1).  
 
Table 3.2-1: Characteristics of cases with Alzheimer’s disease and controls 
  
No. of Cases (%) No. of Controls (%) OR Unadjusted OR Adjusted* 
  
(n = 7086) (n = 7086) (95% CI) (95% CI) 
Age [years] 
        
65–74  1305 (18.4) 1306 (18.4) NA NA 
75–84  3668 (51.8) 3672 (51.8) NA NA 
≥85  2113 (29.8) 2108 (29.8) NA NA 
 
        
Sex 
        
Male 2198 (31.0) 2198 (31.0) NA NA 
Female 4888 (69.0) 4888 (69.0) NA NA 
 
        
Smoking status 
        
None 4182 (59.0) 4029 (56.9) 1.00 (Reference) 1.00 (Reference) 
Current  597 (8.4) 669 (9.4) 0.85 (0.76–0.96) 0.78 (0.69–0.88) 
Past 1626 (23.0) 1692 (23.9) 0.92 (0.84–1.00) 0.94 (0.86–1.03) 
Unknown 681 (9.6) 696 (9.8) 0.94 (0.82–1.07) 0.88 (0.76–1.02) 
 
        
BMI [kg/m2] 
        
≤18.4 308 (4.4) 162 (2.3) 1.49 (1.21–1.82) 1.47 (1.20–1.81) 
18.5–24.9 2907 (41.0) 2243 (31.7) 1.00 (Reference) 1.00 (Reference) 
25–29.9 1762 (24.9) 2189 (30.9) 0.61 (0.56–0.67) 0.63 (0.58–0.69) 
≥30 564 (8.0) 970 (13.7) 0.44 (0.39–0.50) 0.46 (0.41–0.52) 
Unknown 1545 (21.8) 1522 (21.5) 0.79 (0.72–0.87) 0.78 (0.70–0.87) 
 
        
Comorbidities† 
        
Hypertension 2627 (37.1) 3345 (47.2) 0.64 (0.60–0.69) 0.68 (0.63–0.73) 
Dyslipidemia 643 (9.1) 726 (10.3) 0.86 (0.77–0.97) 0.95 (0.84–1.07) 
         
 
*Adjusted for all variables in this table. 
†Patients with a recorded diagnosis.  
No. = Number, OR = Odds Ratio, CI = Confidence Interval, BMI = Body Mass Index, NA = Not Applicable 
 
Overall, patients with diabetes mellitus did not have an altered risk of developing AD 
as compared to those without diabetes (adj. OR 0.99, 95% CI 0.87–1.12). However, 
there was a suggestion of a slightly increased risk with increasing diabetes duration 
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(adj. OR 1.33, 95% CI 1.09–1.63 in patients with diabetes duration ≥10 years. 
Patients with diabetes who did not receive any drug treatment (adj. OR 0.88, 95% CI 
0.71–1.10) and patients who controlled their diabetes with antidiabetic drugs (adj. OR 
1.03, 95% CI 0.90–1.19) were at a similar risk of developing AD as compared to 
patients without diabetes (Table 3.2-2).  
 
Table 3.2-2: Relative risk estimates of developing Alzheimer’s disease in patients with diabetes 
mellitus receiving various antidiabetic drugs 
  
No. of Cases (%) No. of Controls (%) OR Unadjusted OR Adjusted* 
  
(n = 7086) (n = 7086) (95% CI) (95% CI) 
Diabetes mellitus 
        
No 6516 (92.0) 6339 (89.5) 1.00 (Reference) 1.00 (Reference) 
Yes 570 (8.0) 747 (10.5) 0.75 (0.67–0.84) 0.99 (0.87–1.12) 
         
Diabetes mellitus duration 
        
<2 years 102 (1.4) 164 (2.3) 0.61 (0.47–0.78) 0.78 (0.60–1.00) 
2–4.9 years 113 (1.6) 163 (2.3) 0.68 (0.53–0.87) 0.91 (0.70–1.17) 
5–9.9 years 132 (1.9) 199 (2.8) 0.65 (0.52–0.81) 0.86 (0.68–1.09) 
≥10 years 223 (3.2) 221 (3.1) 0.98 (0.81–1.19) 1.33 (1.09–1.63) 
         
Diabetes mellitus treatment 
        
No 155 (2.2) 218 (3.1) 0.70 (0.57–0.86) 0.88 (0.71–1.10) 
Yes 415 (5.9) 529 (7.5) 0.77 (0.67–0.87) 1.03 (0.90–1.19) 
         
Metformin 
        
None 6802 (96.0) 6736 (95.1) 1.00 (Reference) 1.00 (Reference) 
1–9 Rx 65 (0.9) 93 (1.3) 0.68 (0.49–0.94) 1.08 (0.75–1.56) 
10–29 Rx 80 (1.1) 85 (1.2) 0.93 (0.69–1.27) 1.47 (1.03–2.09) 
30–59 Rx 63 (0.9) 101 (1.4) 0.61 (0.45–0.84) 0.99 (0.68–1.44) 
≥60 Rx 76 (1.1) 71 (1.0) 1.06 (0.77–1.46) 1.71 (1.12–2.60) 
         
Sulfonylureas 
        
None 6779 (95.7) 6692 (94.4) 1.00 (Reference) 1.00 (Reference) 
1–9 Rx 48 (0.7) 75 (1.1) 0.63 (0.44–0.91) 0.78 (0.53–1.16) 
10–29 Rx 58 (0.8) 98 (1.4) 0.58 (0.42–0.81) 0.74 (0.51–1.06) 
30–59 Rx 83 (1.2) 98 (1.4) 0.84 (0.63–1.13) 1.07 (0.75–1.52) 
≥60 Rx 118 (1.7) 123 (1.7) 0.95 (0.74–1.23) 1.01 (0.72–1.42) 
         
Insulin 
        
None 7008 (98.9) 6954 (98.1) 1.00 (Reference) 1.00 (Reference) 
1–9 Rx 12 (0.2) 25 (0.4) 0.48 (0.24–0.95) 0.47 (0.22–1.01) 
10–29 Rx 17 (0.2) 36 (0.5) 0.47 (0.27–0.84) 0.59 (0.32–1.10) 
30–59 Rx 23 (0.3) 35 (0.5) 0.66 (0.39–1.11) 0.78 (0.44–1.36) 
≥60 Rx 26 (0.4) 36 (0.5) 0.71 (0.43–1.18) 1.01 (0.58–1.73) 
         
 
DEMENTIA PROJECT          METFORMIN AND RISK OF ALZHEIMER’S DISEASE 
61 
Table 3.2-2: cont. 
  
No. of Cases (%) No. of Controls (%) OR Unadjusted OR Adjusted* 
  
(n = 7086) (n = 7086) (95% CI) (95% CI) 
Thiazolidinediones 
        
None 7053 (99.5) 7029 (99.2) 1.00 (Reference) 1.00 (Reference) 
1–9 Rx 14 (0.2) 25 (0.4) 0.54 (0.28–1.06) 0.89 (0.42–1.86) 
10–29 Rx 12 (0.2) 21 (0.3) 0.57 (0.28–1.16) 0.97 (0.45–2.07) 
≥30 Rx 7 (0.1) 11 (0.2) 0.64 (0.25–1.64) 0.87 (0.31–2.40) 
         
 
*Adjusted for all antidiabetic drug classes in this table plus smoking, BMI, hypertension, dyslipidemia, use of angiotensin 
converting enzyme (ACE) inhibitors, and statins. 
No. = Number, OR = Odds Ratio, CI = Confidence Interval, Rx = Prescriptions 
 
In the main analysis, in which we compared users of metformin or other antidiabetic 
drugs to non-users of the corresponding drugs, long-term use of metformin of ≥60 
prescriptions was associated with an increased risk of developing AD (adj. OR 1.71, 
95% CI 1.12–2.60), although there was no consistent duration effect, i.e. no steady 
risk increase with increasing number of prescriptions. The risks of developing AD in 
long-term users of ≥60 prescriptions of sulfonlyureas (adj. OR 1.01, 95% CI 0.72–
1.42) or ≥30 prescriptions of thiazolidinediones (adj. OR 0.87, 95% CI 0.31–2.40) 
were not materially altered as compared to non-users of the corresponding drugs. 
The same was true for long-term users of ≥60 prescriptions of insulin (adj. OR 1.01, 
95% CI 0.58–1.73) (Table 3.2-2). 
In the second model, in which we compared mutually exclusive groups of users of 
metformin only, sulfonylureas only, thiazolidinediones only, or insulin only with the 
reference group of patients without a diagnosis of diabetes, we did not observe an 
increased risk for AD in long-term users of either metformin or sulfonylureas (Table 
3.2-3). As there were only small numbers of patients who were prescribed insulin 
only or thiazolidinediones only, no meaningful analysis was possible and the results 
are not displayed. 
 
DEMENTIA PROJECT          METFORMIN AND RISK OF ALZHEIMER’S DISEASE 
62 
Table 3.2-3: Relative risk estimates of developing Alzheimer’s disease in patients with diabetes 
mellitus receiving antidiabetic monotherapy with metformin or sulfonylureas only 
  
No. of Cases (%) No. of Controls (%) OR Unadjusted OR Adjusted* 
  
(n = 7086) (n = 7086) (95% CI) (95% CI) 
No diabetes mellitus 6516 (92.0) 6339 (89.5) 1.00 (Reference) 1.00 (Reference) 
         
Metformin only 
        
1–9 Rx 27 (0.4) 31 (0.4) 0.83 (0.50–1.40) 1.24 (0.72–2.13) 
10–29 Rx 25 (0.4) 25 (0.4) 0.98 (0.56–1.71) 1.57 (0.88–2.81) 
≥30 Rx 20 (0.3) 29 (0.4) 0.67 (0.38–1.19) 1.00 (0.55–1.81) 
         
Sulfonylureas only 
        
1–9 Rx 23 (0.3) 40 (0.6) 0.56 (0.33–0.94) 0.69 (0.40–1.20) 
10–29 Rx 23 (0.3) 37 (0.5) 0.60 (0.36–1.03) 0.68 (0.39–1.17) 
≥30 Rx 45 (0.6) 44 (0.6) 1.01 (0.67–1.54) 1.19 (0.77–1.84) 
         
Others† 252 (3.6) 323 (4.6) 0.76 (0.64–0.90) 1.05 (0.88–1.26) 
         
 
*Adjusted for smoking, BMI, hypertension, dyslipidemia, use of angiotensin converting enzyme (ACE) inhibitors, and statins. 
†Further stratification into categories of users of thiazolidinediones only or insulin only was not meaningful due to low numbers of 
exposed patients. This category also includes patients with diabetes mellitus receiving prescriptions for two or more different 
antidiabetic drugs or switching between antidiabetic drugs.  
No. = Number, OR = Odds Ratio, CI = Confidence Interval, Rx = Prescriptions 
 
3.2.5 Discussion 
The findings of this large case-control study do not provide evidence that use of 
metformin is associated with a reduced risk of developing AD. Our findings even 
suggest that long-term use of metformin may be associated with a slightly higher risk 
of developing AD than non-use of this drug, while such a finding was not seen for use 
of other antidiabetic drugs such as sulfonylureas, thiazolidinediones, or insulin. This 
finding supports evidence from the animal study by Chen et al. who observed that 
metformin increased the generation of Aβ protein, which is pivotal in the genesis of 
AD.125 However, the findings regarding the effect of metformin have to be interpreted 
with caution, as this increased risk was not confirmed in a subgroup analysis of users 
of metformin only, and as there was no consistent trend towards an increased risk 
with increasing number of prescriptions.  
In our study, short-term users of insulin had a substantially reduced risk of developing 
AD as compared to non-users of this drug, whereas in long-term users no risk 
alteration was observed. A possible explanation for this could be that diabetic 
DEMENTIA PROJECT          METFORMIN AND RISK OF ALZHEIMER’S DISEASE 
63 
patients who show signs of cognitive impairment, but who are not yet diagnosed with 
dementia, are less likely to be started on insulin therapy than diabetics whose 
cognitive abilities are not impaired and who can comply with treatment. 
Our findings are largely consistent with those of a recent study by Xu et al. who 
explored the risk of developing AD in a cohort of 1,248 dementia-free patients in 
association with diabetes mellitus and glycemic control. Patients with diagnosed 
diabetes mellitus at baseline did not have an increased risk of developing AD during 
follow-up, whereas patients with borderline diabetes were at a marginally increased 
risk of AD.  A subgroup of patients with undiagnosed diabetes mellitus at baseline but 
elevated blood glucose levels ≥11 mmol/L during follow-up exhibited an increased 
risk of AD.126 In contrast with our findings, patients with diabetes who were treated 
with insulin had the highest risk of developing AD as compared to patients without 
diabetes in the Rotterdam study.117 However, the authors of this study stated that 
they could not rule out the possibility of having misclassified subjects with vascular 
dementia as patients with AD. Since diabetes mellitus has been clearly linked to a 
higher risk of developing vascular dementia,120,127 this misclassification may have 
distorted the relative risk estimates for the association between diabetes and AD in 
the Rotterdam study.117  
Our finding of a slightly increased risk of AD and metformin use in this large 
observational study is consistent with observations from a recent in vitro study, in 
which metformin was found to increase the biogenesis of Aβ protein.125 By contrast, 
in other in vitro studies, metformin modified important steps in the biogenesis of 
neuritic plaques and neurofibrillary tangles, or improved impaired neuronal insulin 
signaling,123,124 raising speculations about the potential to reduce the risk of 
developing AD. However, all these observations were made in cortical neurons of 
mice and the results may not be applicable to humans. 
We also examined the role of thiazolidinediones on the risk of developing AD and 
found that diabetic patients treated with these drugs had no risk alteration as 
compared to non-users of these drugs. In animal models of AD, thiazolidinediones 
have been shown to ameliorate disease-related pathology and to improve learning 
and memory deficits.128 Based on these observations, the efficacy of various 
thiazolidinediones (mainly rosiglitazone) in improving cognitive deficits in patients 
with AD has been tested in clinical trials, however with inconsistent findings. While 
Watson et al. reported cognitive improvement after six months of rosiglitazone 
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treatment in patients with mild AD as compared to placebo-treated controls,129 Risner 
et al. found such an association only in individuals with apolipoprotein E (ApoE) ε4 
negative status.130 A recent phase III trial, in which subjects were stratified by ApoE 
ε4 status, extended-release rosiglitazone did not improve cognition in patients with 
mild-to-moderate AD neither in the ApoE ε4 negative nor in the other subgroups.131  
A limitation of our study which needs consideration is that the diagnosis of AD and of 
other dementia types is not straightforward, and the recording of the diagnosis in a 
primary care record is by definition delayed, i.e. it does not occur until after a patient 
has suffered from symptoms for a certain period of time prior to the actual recording 
date. Thus, as with many other slowly developing degenerative diseases, the disease 
onset and therefore the index date in an observational study is not a precise point in 
time. This may affect some risk estimates, particularly if early symptoms of the 
diseases of interest may affect the likelihood of beginning or stopping a given drug 
therapy prior to the actual index date, potentially leading to spuriously low or high risk 
estimates for current short-term use, as may have occurred in short-term users of 
insulin in the present study. We looked at long-term use of each study drug in order 
to account for the unknown date of disease onset and found that long-term use was 
not associated with the risk of AD. Further, some degree of outcome misclassification 
is likely to occur as not all dementia diagnoses can be assigned to a certain subtype 
with certainty. It is, however, a strength of our study that we selected cases through 
use of a questionnaire and by defining a sophisticated algorithm to classify cases in 
the absence of any knowledge of the exposure of interest. The validity of this 
algorithm was corroborated by the fact that up to 80% of all our potential AD cases 
were confirmed by the GP using accepted diagnostic criteria for an AD diagnosis. 
This point is of great importance since diabetes mellitus is clearly associated with VD, 
and significant misclassification could have spuriously increased the risk in our study. 
Diagnostic bias might have played a role in our study since diabetic patients may be 
more likely of getting an AD diagnosis as the result of a closer follow up by the GP 
than patients without diabetes. However, the reverse is also possible because 
patients with long-standing severe diabetes mellitus may be less likely to be 
investigated for AD. 
We were not able to adjust for certain potential confounders such as ApoE ε4 allele,73 
level of education,132 or certain lifestyle factors such as physical activity133 or dietary 
habits,68 since these factors are not regularly recorded in the GPRD. However, we 
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adjusted for BMI which is to some degree related to physical activity and dietary 
habits.  
In summary, the findings of this large observational study do not provide evidence 
that use of metformin reduces the risk of developing AD. We even found that long-
term use of metformin, as opposed to use of other antidiabetic drugs, was associated 
with a suggestion of an increased risk, but there was not a consistent trend with 
increasing number of prescriptions, and the result was not confirmed in a subgroup 
analysis of patients prescribed metformin only. Long-term use of sulfonylureas, 
thiazolidinediones, or insulin was not associated with an altered risk of developing AD 
in patients with diabetes mellitus.  
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3.3.1 Abstract 
Purpose: Patients with Alzheimer’s disease (AD) have an increased risk of 
developing seizures or epilepsy. Little is known about the role of risk factors and 
about the risk of developing seizures/epilepsy in patients with vascular dementia 
(VD). The aim of this study was to assess incidence rates (IRs) of seizures/epilepsy 
in patients with AD, VD or without dementia, and to identify potential risk factors of 
seizures or epilepsy. 
Methods: We conducted a follow-up study with a nested case-control analysis using 
the UK-based General Practice Research Database (GPRD). We identified patients 
aged ≥65 years with an incident diagnosis of AD or VD between 1998 and 2008 and 
a matched comparison group of dementia-free patients. Conditional logistic 
regression was used to estimate the odds ratio (OR) with 95% confidence intervals 
(CIs) of developing seizures/epilepsy in patients with AD or VD, stratified by age at 
onset and duration of dementia as well as by use of anti-dementia drugs.  
Key findings: Among 7,086 cases with AD, 4,438 with VD, and 11,524 matched 
dementia-free patients we identified 180 cases with an incident diagnosis of 
seizures/epilepsy. The IRs of epilepsy/seizures for patients with AD or VD were 
5.6/1,000 person-years (py) (95% CI 4.6–6.9) and 7.5/1,000 py (95% CI 5.7–9.7), 
respectively, and 0.8/1,000 py (95% CI 0.6–1.1) in the dementia-free group. In the 
nested case-control analysis, patients longer standing (≥3 years) AD had a slightly 
higher risk of developing seizures or epilepsy than those with a shorter disease 
duration, while in patients with VD the contrary was observed.  
Significance: Seizures or epilepsy were substantially more common in patients with 
AD and VD than in dementia-free patients. The role of disease duration as a risk 
factor of seizures/epilepsy seems to differ between AD and VD.   
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3.3.2 Introduction 
Several epidemiological studies have consistently shown that patients with 
Alzheimer’s disease (AD) are at a higher risk of developing seizures or epilepsy than 
patients without dementia,134-138 a finding which is supported by mechanistic studies 
of seizures in models of AD.139 However, relative risk estimates vary considerably 
between studies, ranging from a 6-fold higher risk in one study135 to a 10-fold higher 
risk in another study,134 depending – among other factors – on whether AD patients 
were recruited from a special care facility or from a population-based setting. 
Moreover, the role of different predictors of seizures or epilepsy in patients with AD is 
controversially discussed. While younger age at AD onset was found to be 
associated with an increased risk of developing seizures in one study,140 others did 
not find such an association.134,136 There is also conflicting evidence on whether a 
longer duration of AD is associated with an increased risk of seizures.138,141,142 In 
addition, the role of specific anti-dementia drugs such as the acetylcholinesterase 
inhibitors (AChEIs) or memantine is also largely unclear. Limited evidence from case 
reports suggests that AChEIs such as donepezil143 or tacrine144 may provoke 
seizures in patients with AD. In animal studies, memantine was found to have both 
pro- and anticonvulsive properties.145 However, large observational studies exploring 
a possible association between use of these drugs and an altered risk of developing 
seizures in patients with AD are lacking.  
To our knowledge, there is only one study assessing the risk of incident seizures in 
patients with dementia forms other than AD;135 however, in that particular study, the 
risk estimate was calculated for a mixed subgroup of ‘other dementias’ which 
contained all other possible dementia subtypes, such as vascular dementia (VD), 
Lewy body dementia, and other forms.  
The aim of this study was to assess incidence rates of seizures or epilepsy in 
patients with AD or VD as well as in dementia-free patients, and to further explore the 
role of various predictors of seizures in these patients within a population-based 
setting. 
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3.3.3 Methods 
Data source 
We used the UK-based General Practice Research Database (GPRD) which was 
established in around 1987 and encompasses data on some 11 million patients who 
are or were registered with selected general practitioners (GPs).100 The patients 
enrolled in the GPRD are representative of the UK population with regard to age, sex, 
geographic distribution, and annual turnover rate. The GPs have been trained to 
record medical information for research purposes in a standardized manner. The 
information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, and hospitalizations. Since the doctors generate drug prescriptions 
directly with the computer using a coded drug dictionary, all recorded prescriptions 
include the name of the preparation, route of administration, dose of a single unit, 
number of units prescribed and, in most instances, intake regimen. The database has 
been described in detail elsewhere101,102 and validated extensively.103,104 
The study was approved by ISAC, the Independent Scientific Advisory Committee for 
Medicines and Healthcare products Regulatory Agency (MHRA) database research. 
 
Study population 
The study population consisted of patients aged 65 years or more with a diagnosis of 
AD or VD between January 1998 and September 2008, identified through a validated 
algorithm described in detail in chapter 3.1.3, and a comparison group of dementia-
free patients of the same number, matched to AD or VD patients on age (i.e. same 
year of birth), sex, GP, calendar time (i.e. the date when the case developed AD or 
VD), and number of years of recorded history in the database. Patients with less than 
three years of recorded history prior to the AD or VD diagnosis (or the corresponding 
date in the dementia-free comparison group), as well as those with a history of 
HIV/AIDS, alcoholism, drug abuse, multiple sclerosis, motor neuron disease, or 
Down’s syndrome were excluded. 
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Follow-up and identification of incident seizures or epilepsy cases 
In a first step we excluded all patients from the study population with a history of 
(diagnosed) epilepsy or seizures prior to the AD or VD diagnosis (or the 
corresponding date in the dementia-free comparison group). We then followed all 
patients until they developed a first-time diagnosis of epilepsy or seizures, died, or 
follow-up ended in the medical record, whichever came first. The date of the 
epilepsy/seizures diagnosis will subsequently be referred to as the ‘index date’. 
Patients with more than three prescriptions for an anticonvulsant drug prior to the 
index date were excluded because they were considered to be prevalent rather than 
incident cases. As not all patients with diagnosed epilepsy or seizures need 
treatment with an anticonvulsant drug, the remaining patients with a recorded 
epilepsy or seizure code, but no treatment code ±90 days around the index date, 
were also included in the analyses. However, to verify the validity of our epilepsy or 
seizure cases, we ran a sensitivity analysis in those cases with a treatment code ±90 
days around the index date, where a diagnosis of epilepsy may be more likely. 
 
Nested case-control analysis 
For each case patient with an incident diagnosis of epilepsy or seizures we identified 
at random up to four control patients from the study population who did not develop 
epilepsy or seizures during follow-up. We matched controls to case patients on age 
(i.e. year of birth, ±3 years), sex and calendar time (i.e. the date when the case 
developed epilepsy). For both cases and controls we assessed the prevalence of 
diagnosed AD or VD prior to the index date and stratified patients with AD or VD by 
age (65–79 and ≥80 years), age at dementia onset (65–79 and ≥80 years), and 
disease duration of diagnosed dementia (<1, 1–2.9, and ≥3 years). Patients with AD 
were additionally stratified by treatment, i.e. on the basis of whether they were 
treated with an anti-dementia drug (i.e. an AChEI and/or memantine) or not, taking 
into consideration the timing of the last prescription prior to the index date (‘past’, if 
last prescription ≥90 days, or ‘current’, if last prescription <90 days). Patients being 
treated with an anti-dementia drug were further stratified into those receiving AChEIs 
only, memantine only, or both. 
 
DEMENTIA PROJECT          SEIZURES IN ALZHEIMER’S DISEASE 
72 
Statistical analysis 
In the follow-up analysis we assessed person-time for all patients in the study 
population from the date of first AD or VD diagnosis (or the corresponding date in the 
dementia-free comparison group) until a patient developed a first-time diagnosis of 
epilepsy or seizures, died, or follow-up ended in the medical record. We assessed 
crude incidence rates (IRs) with 95% confidence intervals (CIs) of epilepsy/seizures 
for patients with AD, VD or without dementia, stratified by age (65–79 and ≥80 years) 
and sex. We then calculated corresponding age- and sex-stratified crude incidence 
rate ratios (IRRs) with 95% CIs of epilepsy/seizures for patients with AD or VD, 
compared to the group of patients without dementia.  
In the nested case-control analysis we conducted conditional logistic regression 
analyses using the statistical software SAS, version 9.2 (SAS Institute, Inc., Cary, 
NC, USA). We calculated relative risk estimates as odds ratios (ORs) with 95% 
confidence intervals (CIs). The analyses were controlled for the potential confounders 
age, sex, and calendar time by matching, and further adjusted for body mass index 
(BMI) (≤18.4, 18.5–24.9, 25–29.9, ≥30 kg/m2 or unknown), a history of diagnosed 
stroke, transient ischemic attack (TIA) or of a head injury, as well as for current use 
(i.e. the last prescription ≤90 days prior to the index date) of antidepressants or 
antipsychotics in the multivariate model. Other potential confounders such as 
smoking status (non, current, past, or unknown), arterial hypertension, dyslipidemia, 
diabetes mellitus, current use of antiplatelet drugs, anticoagulants, or statins were 
also tested in multivariate analyses; however, as they had no material impact on the 
risk estimates for the association of interest, they were not included in the final 
multivariate model. 
 
3.3.4 Results 
The initial study population consisted of 7,086 patients with AD, 4,438 patients with 
VD, and 11,524 matched comparison subjects without a diagnosis of dementia. VD 
patients were on average slightly older at the time of diagnosis than the AD patients 
(mean age [±std.] 82.2 [±6.6] years vs. 80.7 [±6.7] years), whereas the proportion of 
females was higher among AD patients (69% AD vs. 59% VD). The proportion of 
underweight (BMI ≤18.4 kg/m2) subjects was higher in both AD and VD patients than 
in the corresponding comparison group, while the opposite was true for the 
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proportion of overweight (BMI 25–29.9 kg/m2) or obese (BMI ≥30 kg/m2) subjects. 
Patients with VD were more frequently current smokers than the corresponding 
comparison subjects (Table 3.3-1).  
 
Table 3.3-1: Characteristics of patients with Alzheimer’s disease or vascular dementia and the 
corresponding matched comparison subjects without dementia 
    
No. of AD 
patients (%) 
No. of 
comparison 
subjects (%) 
OR (95% CI) 
 
No. of VD 
patients (%) 
No. of 
comparison 
subjects (%) 
OR (95% CI) 
    
(n = 7086) (n = 7086)  
 
(n = 4438) (n = 4438)   
Age [years]  
             
65–69  410 (5.8) 411 (5.8) NA  157 (3.5) 156 (3.5) NA 
70–74 895 (12.6) 895 (12.6) NA  441 (9.9) 444 (10.0) NA 
75–79 1639 (23.1) 1638 (23.1) NA  882 (19.9) 880 (19.8) NA 
80–84 2029 (28.6) 2034 (28.7) NA  1254 (28.3) 1266 (28.5) NA 
85–90 1477 (20.8) 1475 (20.8) NA  1123 (25.3) 1114 (25.1) NA 
≥90 636 (9.0) 633 (8.9) NA  581 (13.1) 578 (13.0) NA 
              
Sex  
             
Male 2198 (31.0) 2198 (31.0) NA  1801 (40.6) 1801 (40.6) NA 
Female  4888 (69.0) 4888 (69.0) NA  2637 (59.4) 2637 (59.4) NA 
              
Smoking status  
             
None 4182 (59.0) 4029 (56.9) 1.0 (Ref)  2370 (53.4) 2497 (56.3) 1.0 (Ref) 
Current  597 (8.4) 669 (9.4) 0.9 (0.8−1.0)  522 (11.8) 382 (8.6) 1.5 (1.3–1.7) 
Past 1626 (23.0) 1692 (23.9) 0.9 (0.8−1.0)  1145 (25.8) 1133 (25.5) 1.1 (1.0–1.2) 
Unknown 681 (9.6) 696 (9.8) 0.9 (0.8−1.1)  401 (9.0) 426 (9.6) 1.0 (0.8–1.2) 
              
BMI [kg/m2]  
             
≤18.4 308 (4.4) 162 (2.3) 1.5 (1.2−1.8)  197 (4.4) 107 (2.4) 1.7 (1.3–2.1) 
18.5–24.9 2907 (41.0) 2243 (31.7) 1.0 (Ref)  1663 (37.5) 1456 (32.8) 1.0 (Ref) 
25–29.9 1762 (24.9) 2189 (30.9) 0.6 (0.6−0.7)  1106 (24.9) 1356 (30.6) 0.7 (0.6–0.8) 
≥30 564 (8.0) 970 (13.7) 0.4 (0.4−0.5)  439 (9.9) 550 (12.4) 0.7 (0.6–0.8) 
Unknown 1545 (21.8) 1522 (21.5) 0.8 (0.7−0.9)  1033 (23.3) 969 (21.8) 1.0 (0.9–1.1) 
                              
 
No. = Number, AD = Alzheimer's Disease, VD = Vascular  Dementia, OR = Odds Ratio, CI = Confidence Interval, BMI = Body 
Mass Index, NA = Not applicable, Ref = Reference Group 
 
Incidence rates of epilepsy or seizures  
After excluding patients with a history of diagnosed epilepsy or seizures from the 
initial study population, 6,932 cases with AD, 4,205 with VD, and 11,321 dementia-
free matched comparison subjects remained for follow-up. Within this study 
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population, we identified 207 cases with an incident diagnosis of epilepsy or seizures 
of which 180 (87%) met our predefined inclusion and exclusion criteria. The median 
follow-up time from the date of dementia diagnosis (or the corresponding date in the 
comparison group) to the index date was 1.5 years (interquartile range [IQR] 0.5–3.0 
years). Of these 180 cases, 97 had a history of AD, 55 a history of VD, and 28 had 
no history of dementia. 
Overall, the IR of epilepsy or seizures for patients with AD, VD, or no dementia was 
5.6/1,000 person-years (py) (95% CI 4.6–6.9), 7.5/1,000 py (95% CI 5.7–9.7), and 
0.8/1,000 py (95% CI 0.6–1.1), respectively. The corresponding crude IRR was 7.1 
(95% CI 4.9–10.3) for patients with AD, and 9.3 (95% CI 5.3–16.5) for patients with 
VD with the no dementia group as the referent. Sex- and age-specific IRs and 
corresponding IRRs are displayed in Table 3.3-2. For patients with VD, but not AD, a 
higher age-specific IR and corresponding IRR was observed in those aged 65–79 
years compared to those aged ≥80 years, although this difference was not 
statistically significant. 
 
Table 3.3-2: Incidence rates of epilepsy/seizures in patients with Alzheimer’s disease, vascular 
dementia, or no dementia, and corresponding incidence rate ratios, stratified by age and sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR = Incidence Rate, IRR = Incidence Rate Ratio, CI = Confidence Interval, Ref = Reference Group 
  
Person-
years 
Cases 
(n=180) 
IR/1,000 person-
years (95% CI) IRR (95% CI) 
No dementia 
      
All 35217 28 0.8 (0.6–1.1) 1.0 (Ref) 
Men 12123 10 0.8 (0.4–1.5) 1.0 (Ref) 
Women 23094 18 0.8 (0.5–1.2) 1.0 (Ref) 
Age 65–79 years 11447 9 0.8 (0.4–1.5) 1.0 (Ref) 
Age ≥80 years 23770 19 0.8 (0.5–1.2) 1.0 (Ref) 
       
Alzheimer's disease 
      
All 17178 97 5.6 (4.6–6.9) 7.1 (4.9–10.3) 
Men 5148 26 5.1 (3.4–7.4) 6.1 (3.0–12.4) 
Women 12031 71 5.9 (4.7–7.4) 7.5 (4.9–11.7) 
Age 65–79 years 6336 39 6.2 (4.5–8.4) 7.8 (4.3–14.0) 
Age ≥80 years 10842 58 5.3 (4.1–6.9) 6.7 (4.1–10.8) 
       
Vascular dementia 
      
All 7365 55 7.5 (5.7–9.7) 9.3 (5.3–16.5) 
Men 2887 25 8.7 (5.9–12.8) 10.4 (4.5–24.1) 
Women 4478 30 6.7 (4.7–9.5) 8.5 (4.0–18.4) 
Age 65–79 years 2303 24 10.4 (7.0–15.5) 13.1 (5.3–32.6) 
Age ≥80 years 5061 31 6.1 (4.3–8.7) 7.6 (3.7–15.8) 
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Nested case-control analysis 
The analysis encompassed 180 case patients with an incident diagnosis of epilepsy 
or seizures, and 689 matched control patients (34% male patients). The 
characteristics of cases and controls are displayed in Table 3.3-3.  
 
Table 3.3-3: Characteristics of cases with epilepsy or seizures and corresponding controls 
  
No. of cases (%) No. of controls (%) OR unadjusted  OR adjusted* 
  
(n = 180) (n = 689) (95% CI) (95% CI) 
Sex         
Male 61 (33.9) 237 (34.4)     
Female 119 (66.1) 452 (65.6)     
         
Age [years] 
        
65–79 72 (40.0) 275 (39.9)     
≥80 108 (60.0) 414 (60.1)     
         
BMI (kg/m2) 
        
12–18.4 4 (2.2) 15 (2.2) 1.0 (Ref) 1.0 (Ref) 
18.5–24.9 71 (39.4) 237 (34.4) 0.9 (0.3–2.7) 1.2 (0.4–4.2) 
25–29.9 46 (25.6) 184 (26.7) 0.8 (0.6–1.3) 0.9 (0.5–1.4) 
30–60 15 (8.3) 81 (11.8) 0.6 (0.3–1.2) 0.6 (0.3–1.1) 
Unknown 44 (24.4) 172 (25.0) 0.9 (0.6–1.4) 0.9 (0.6–1.5) 
         
Comorbidities         
Stroke/TIA 76 (42.2) 119 (17.3) 3.6 (2.5–5.2) 3.2 (2.1–4.6) 
Head injury 22 (12.2) 36 (5.2) 2.6 (1.5–4.6) 2.0 (1.1–3.8) 
         
Drugs         
Antidepressants 49 (27.2) 108 (15.7) 2.4 (1.6–3.6) 1.7 (1.1–2.7) 
Antipsychotics 33 (18.3) 55 (8.0) 3.5 (2.1–5.8) 2.9 (1.7–5.0) 
                  
 
*Adjusted for all covariates this table.  
TIA = Transient Ischemic Attack , OR = Odds Ratio, CI = Confidence Interval, Ref = Reference Group 
 
As compared to patients without dementia, the relative risk estimate (OR) of 
developing seizures or epilepsy in association with AD was 6.6 (95% CI 4.1–10.6), 
after adjusting for the potential confounders BMI, stroke or TIA, head injury, and 
current use of antidepressants or antipsychotics. Neither younger age at index date 
(65–79 years) nor younger age at AD onset (65–79 years) were related to an altered 
risk of developing seizures or epilepsy compared to those aged ≥80 years or to those 
with the AD onset at or after the age of 80 years, respectively. Patients with longer 
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standing (≥3 years) AD had a higher risk of developing seizures or epilepsy than 
those with a shorter duration of disease, although this difference was not statistically 
significant. The risk of developing seizures or epilepsy was not materially different 
among patients with AD receiving treatment with anti-dementia drugs compared to 
patients without drug treatment for AD (Table 3.3-4). 
As compared to patients without dementia, the relative risk estimate (OR) of 
developing seizures or epilepsy in association with VD was 5.7 (95% CI 3.2–10.1), 
after adjusting for the potential confounders BMI, stroke or TIA, head injury, and 
current use of antidepressants or antipsychotics. Neither age at index date nor age at 
VD onset materially altered the risk of developing seizures or epilepsy. However, 
there was an increased risk of seizures or epilepsy in patients with shorter duration 
(<1 year) VD compared to cases with longer disease duration, though statistical 
significance was not reached (Table 3.3-4). 
The sensitivity analysis in those patients with a prescription of an anticonvulsant drug 
± 90 days around the index date revealed similar results (as the main analysis). 
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Table 3.3-4: Risk of developing epilepsy or seizures in patients with Alzheimer’s disease or vascular 
dementia, stratified by age, age at dementia onset, duration of dementia, or specific Alzheimer’s 
disease treatment 
  
No. of cases (%) No. of controls (%) OR unadjusted  OR adjusted* 
  
(n = 180) (n = 689) (95% CI) (95% CI) 
 
        
No dementia 28 (15.6) 448 (65.0) 1.0 (Reference) 1.0 (Reference) 
  
Alzheimer's disease 97 (53.9) 164 (23.8) 7.0 (4.5–10.9) 6.6 (4.1–10.6) 
Age [years] 
65–79 39 (21.7) 68 (9.9) 7.2 (3.8–13.8) 7.1 (3.5–14.4) 
≥80 58 (32.2) 96 (13.9) 6.8 (4.0–11.5) 6.2 (3.5–10.9) 
 
Age at onset [years] 
65–79 62 (34.4) 103 (15.0) 7.6 (4.5–12.9) 6.9 (3.9–12.1) 
≥80 35 (19.4) 61 (8.9) 6.1 (3.3–11.3) 6.1 (3.2–11.8) 
        
Duration [years] 
        
<1 27 (15.0) 60 (8.7) 5.0 (2.7–9.1) 5.3 (2.8–10.2) 
1–2.9 35 (19.4) 64 (9.3) 6.4 (3.7–11.2) 5.7 (3.2–10.3) 
≥3 35 (19.4) 40 (5.8) 11.7 (6.3–22.0) 10.7 (5.4–21.4) 
Treatment 
No 48 (26.7) 89 (12.9) 6.6 (4.0–11.1) 6.2 (3.6–10.8) 
Past 16 (8.9) 21 (3.1) 8.7 (4.0–19.0) 7.5 (3.2–17.6) 
Current 33 (18.3) 54 (7.8) 6.9 (3.8–12.5) 6.7 (3.6–12.6) 
AChEIs only 31 (17.2) 51 (7.4) 7.0 (3.8–12.7) 6.9 (3.6–13.1) 
Memantine only 2 (1.1) 1 (0.2) 22.2 (1.9–256.5) 19.5 (1.6–237.1) 
Both 0 (0.0) 2 (0.3) – – 
Vascular dementia 55 (30.6) 77 (11.2) 8.9 (5.3–15.0) 5.7 (3.2–10.1) 
Age [years] 
65–79 24 (13.3) 24 (3.5) 11.0 (5.1–23.8) 6.8 (2.9–16.4) 
≥80 31 (17.2) 53 (7.7) 7.6 (3.9–14.8) 5.1 (2.5–10.2) 
 
Age at onset [years] 
65–79 28 (15.6) 31 (4.5) 10.4 (5.3–20.5) 6.2 (2.9–13.2) 
≥80 27 (15.0) 46 (6.7) 7.6 (3.8–15.2) 5.3 (2.5–11.0) 
Duration [years] 
<1 35 (19.4) 34 (4.9) 12.5 (6.8–23.0) 8.1 (4.2–15.6) 
1–2.9 17 (9.4) 35 (5.1) 6.3 (3.1–12.8) 3.7 (1.7–8.2) 
≥3 3 (1.7) 8 (1.2) 5.5 (1.3–23.1) 3.4 (0.8–15.6) 
                
 
*Adjusted for BMI, stroke/TIA, head injury, and current use of antidepressants or antipsychotics. AChEIs = Acetylcholinesterase 
inhibitors, OR = Odds Ratio, CI = Confidence Interval, Ref = Reference Group 
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3.3.5 Discussion 
In the follow-up analysis of this large epidemiological study we estimated IRs of 
seizures or epilepsy among patients with AD, VD or without dementia, stratified by 
age and sex, and we calculated corresponding crude IRRs where those with no 
recorded diagnosis of dementia comprised the comparison group. For patients with 
AD we found an overall IR of 5.6/1,000 py and for VD we found an IR of 7.5/1,000 py. 
These were both higher than the IR of 0.8/1,000 py that we found for patients without 
dementia, and resulted in elevated IRRs and ORs in the nested case-control 
analysis. 
The IR for AD was somewhat lower than the IR of 8.7/1,000 py reported in another 
study by Amatniek et al., which assessed overall and age-specific IRs of seizures 
among 233 subjects with AD.137 This difference could be explained by the fact that – 
in contrast to our study – younger AD patients were included in the Amatniek et al. 
study. In line with this interpretation, Amatniek et al. found age-specific IRs of 
42.6/1,000 py and 15.5/1,000 py in those aged 50–59 years and 60–69 years, 
respectively. In patients aged 70–79 and in those aged ≥80 years, IRs of 5.7/1,000 
py and 5.5/1,000 py were reported, findings which are closely similar to our results. 
In the nested case-control analysis we calculated an adjusted OR of 6.6 (95% CI 
4.1–10.6) of developing seizures or epilepsy in association with AD, which is 
somewhat lower than the relative risk (RR) of 10.0 (95% CI 4.3–19.7) found in an 
early study by Hauser et al.134 or the hazard ratio (HR) of 8.06 (95% CI 3.23–16.61) 
reported in a more recent study by Scarmeas et al.138 However, reported confidence 
intervals in these two studies were wide and included the point estimate reported in 
our study. In addition, in both these studies,134,138 AD cases were selected from 
special care facilities or specialized diagnostic and treatment centers; thus, these 
patients were presumably at a more advanced stage of their disease compared to 
demented patients selected from the general population in primary care, as in our 
study. As more severe and advanced stages of AD have been reported to be 
associated with a greater risk of seizures or epilepsy,136,137 these patients were 
probably more likely to have seizures or epilepsy than a sample of AD patients 
derived from the general population. Our findings are supported by another 
population-based study which assessed the relative risk of developing seizures in 
association with AD, reporting an approximately 6-fold increased risk (OR 6.2, 95% 
CI 2.2–17.0) as compared to patients without dementia.135 
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In our study, we found that neither younger age at index date, nor younger age at AD 
onset were materially associated with an altered risk of developing seizures or 
epilepsy. The latter finding is supported by the results from a prospective cohort 
study among 44 patients with mild AD and 58 healthy controls, where no difference in 
age at onset of AD between patients who developed seizures and those who did not 
was observed.136 Additionally, in another retrospective analysis, there was no 
difference in age at onset of AD among 81 autopsy-confirmed AD cases between 
those who developed seizures and those who did not.134 However, in a study among 
446 autopsy-confirmed AD cases, patients who developed seizures were, on 
average, younger at age of dementia onset than those who did not develop 
seizures.140 Contrary to our findings, younger age of AD was associated with an 
increased risk of seizures in two prospective cohort studies.137,138 This could possibly 
be due to the fact that both prospective studies used a non-random sample of AD 
patients recruited from tertiary care university hospitals or specialized diagnostic and 
treatment centers, including those with more advanced/severe disease, whereas we 
used a population-based sample. 
In this study, there was a suggestion that patients with a longer standing (≥ 3 years) 
history of diagnosed AD may be at a higher risk of developing seizures or epilepsy 
than those with a shorter duration of disease. However, available evidence from the 
literature is conflicting: While some studies in patients with AD found that seizures 
tended to develop late in the course of the disease,141,142 another study examining 
predictors of new-onset seizures in patients with AD found no increased risk in 
association with longer duration of disease.138 Of note, increasing evidence suggests 
that more severe AD and not primarily longer duration of AD is associated with an 
increased risk of developing seizures.136,137,146 
In our study we did not observe a materially altered risk of seizures or epilepsy in 
patients using AChEIs. In comparison, in a small pilot study assessing the efficacy of 
donepezil to improve memory in patients with epilepsy, there was a small increase in 
frequency of generalized tonic-clonic seizures between the pre- and the post-
administration period of donepezil, though the difference did not reach statistical 
significance.147 In another small randomized controlled trial including 23 epilepsy 
patients there was also a statistically non-significant difference in seizure frequency 
between patients treated with donepezil and those treated with placebo.148 However, 
since occurrence of seizures or epilepsy in AD is overall uncommon,138 one would 
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require a much larger sample size (and/or a longer observation period) to detect a 
statistically significant difference among users of AChEIs compared to nonusers, if it 
exists. 
A major limitation of our study is that we cannot rule out the possibility of AD and VD 
case misclassification as not all dementia diagnoses can be assigned to a certain 
subtype with certainty. It is, however, a strength of our study that we validated cases 
through use of a questionnaire and classified them by defining a sophisticated 
algorithm in the absence of any knowledge of the exposures of interest. The validity 
of this algorithm was corroborated by the fact that up to 80% of all our potential AD 
and up to 75% of all potential VD cases were confirmed by the GP using accepted 
diagnostic criteria for an AD or VD diagnosis. Moreover, there is the potential of 
seizure or epilepsy misclassification in our study, because only a small percentage 
(1%) of all cases was referred to a neurologist to confirm the diagnosis (according to 
GP’s record). However, as the results of a sensitivity analysis in those cases who had 
a recording for an anticonvulsant drug ±90 days around the index date (making a 
diagnosis of epilepsy highly likely, 51% of all incident cases) were not materially 
different to those of our main analysis, we are confident that the potential of seizure 
or epilepsy misclassification could be kept to a minimum. Another limitation is that we 
could not assess the severity of AD (or VD) to verify whether severity rather than the 
duration of the disease was associated with an increased risk of developing seizures 
or epilepsy, because we had no information about patients’ cognitive status from the 
GPs’ record. However, as duration of symptoms has been related to dementia 
severity,149 we used duration of the disease as a rough proxy for the severity.  
Our study also has several strengths. First, we used a large, validated and well-
established primary-care database to study the association between different 
dementia forms and the risk of developing seizures or epilepsy. Since occurrence of 
seizures or epilepsy is uncommon, though more likely in patients with a diagnosis of 
dementia, only use of a large database such as the GPRD allows inclusion of a 
substantial number of patients. In addition, we used a sophisticated and validated 
algorithm to identify only well-defined AD or VD cases in the database that formed 
our study population. 
In summary, patients with AD or VD were at a much higher risk of developing 
seizures or epilepsy than dementia-free patients. Neither younger age, nor younger 
age at dementia onset, nor use of AChEIs were materially associated with an altered 
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risk of developing seizures or epilepsy. However, there was a suggestion that 
patients with longer standing (≥3 years) AD may have a higher risk of developing 
seizures or epilepsy than those with a shorter duration of disease, whereas in 
patients with VD the contrary was observed. 
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3.4.1 Abstract  
Background: Dementia has been associated with stroke, but the magnitude of the 
risk in patients with Alzheimer’s disease (AD) or vascular dementia (VD) is largely 
unknown. 
Objective: To explore the risk of ischemic stroke, hemorrhagic stroke, or transient 
ischemic attack (TIA) in patients with AD or VD. 
Methods: We conducted a follow-up study with a nested case-control analysis using 
the UK-based Clinical Practice Research Datalink (CPRD). We included patients 
aged ≥65 years with an incident diagnosis of AD or VD between 1998 and 2008 and 
a matched comparison group of dementia-free patients. We estimated incidence 
rates (IRs) of ischemic stroke, hemorrhagic stroke, or TIA in patients with AD, VD, or 
without dementia, and we calculated odds ratios (ORs) with 95% confidence intervals 
(CIs) of developing such an outcome in patients with AD or VD, stratified by use of 
antipsychotic drugs.  
Results: We followed 6,443 cases with AD, 2,302 with VD, and 9,984 matched 
dementia-free patients over time and identified 281 cases with incident ischemic 
stroke, 139 with hemorrhagic stroke, and 379 with TIA. The IRs of ischemic stroke for 
patients with AD, VD, and dementia-free controls were 4.7/1,000 person-years (py) 
(95% CI 8.8–12.0), 12.8/1,000 py (95% CI 23.2–33.5), and 5.1/1,000 py (95% CI 
7.8–9.9), respectively. Compared to dementia-free patients, the OR of developing a 
TIA for AD patients treated with atypical antipsychotic drugs was 5.5 (95% CI 2.6–
11.7).  
Conclusions: Patients with VD, but not AD have a markedly higher risk of developing 
an ischemic stroke than those without dementia. In patients with AD, but not VD, use 
of atypical antipsychotic drugs was associated with an increased risk of TIA. 
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3.4.2 Introduction 
Hospital- and population-based studies have indicated that patients with stroke have 
an about twofold increased risk of developing new-onset dementia as compared to 
patients without any history of stroke.62 Conversely, 9–14% of all patients who 
develop a stroke have dementia.150 Results from two population-based studies 
suggested that patients with severe cognitive impairment or with mild dementia had 
more than a twofold increased stroke risk compared to cognitively healthy 
subjects.151,152 The mechanism by which dementia increases the risk of stroke is not 
fully understood. It has been hypothesized that cognitive impairment may be an early 
manifestation of vascular brain injury preceding stroke.151,152 Consistent with this 
hypothesis, the authors from two recent studies found that patients with low cognitive 
test scores were at greater risk of developing a first-time stroke, independent of other 
major vascular risk factors.153,154  
In addition to concerns that dementia itself increases the risk of stroke, concerns 
arose in recent years that use of risperidone or olanzapine, two atypical antipsychotic 
drugs which are used to treat behavioral symptoms in patients with dementia, may 
(also) be associated with an increased risk of stroke.155,156 Subsequently, 
epidemiological studies investigated the association between use of atypical 
antipsychotic drugs and the risk of incident stroke, with controversial findings.157-160 
Recent studies suggest that the risk may not be limited to atypical antipsychotic 
drugs, but that all antipsychotic drugs are associated with an increased risk of stroke 
in demented patients.161-163 
To our knowledge, no population-based study has yet been published that assessed 
the risk of developing stroke in patients diagnosed with specific subtypes of 
dementia, such as Alzheimer’s disease (AD) or vascular dementia (VD), or that 
explored the role of antipsychotic drug use on the risk of developing stroke in patients 
with AD or VD. 
 
3.4.3 Methods 
Data source 
We used the UK-based Clinical Practice Research Datalink (CPRD) which was 
established around 1987 and encompasses data on some 8 million patients who are 
or were registered with selected general practitioners (GPs).100 The patients enrolled 
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in the CPRD are representative of the UK population with regard to age, sex, 
geographic distribution, and annual turnover rate. The GPs have been trained to 
record medical information for research purposes in a standardized manner. The 
information recorded includes patient demographics and characteristics (e.g. age, 
sex, height, weight, smoking status), symptoms, medical diagnoses, referrals to 
consultants, and hospitalizations. Since the doctors generate drug prescriptions 
directly with the computer using a coded drug dictionary, all recorded prescriptions 
include the name of the preparation, route of administration, dose of a single unit, 
number of units prescribed and, in most instances, intake regimen. The database has 
been described in detail elsewhere101,102 and validated extensively.103,104  
The study was approved by ISAC, the Independent Scientific Advisory Committee for 
Medicines and Healthcare products Regulatory Agency (MHRA) database research. 
 
Study population 
The study population consisted of patients aged ≥65 years with a diagnosis of AD or 
VD between January 1998 and September 2008, identified through a validated 
algorithm described in detail in the electronic appendix, and a comparison group of 
dementia-free patients matched one to one to AD or VD patients on age (i.e. same 
year of birth), sex, GP, calendar time (i.e. the date when the case developed AD or 
VD), and number of years of recorded history in the database. Patients with <3 years 
of recorded history prior to the AD or VD diagnosis (or the corresponding date in the 
dementia-free comparison group) or with HIV/AIDS, alcoholism, drug abuse, multiple 
sclerosis, motor neuron disease, or Down’s syndrome were excluded. 
 
Follow-up and identification of stroke or TIA cases 
We excluded all patients from the study population with a history of stroke or 
transient ischemic attack (TIA) prior to the AD or VD diagnosis (or the corresponding 
date in the dementia-free comparison group). We then followed all patients until they 
developed a first-time diagnosis of stroke (defined as either ischemic stroke, 
hemorrhagic stroke, or unspecified stroke) or a TIA, died, or follow-up in the medical 
record ended, whatever came first. The date of the stroke or TIA diagnosis will 
subsequently be referred to as ‘index date’.  
To clearly differentiate between ischemic stroke, hemorrhagic stroke or TIA, we 
developed an algorithm using UK stroke/TIA management guidelines,164,165 which 
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was applied to all potential cases with a recorded code of either ischemic stroke, 
hemorrhagic stroke, unspecified stroke or TIA at the index date.  The algorithm was 
based on recordings of newly started or stopped pharmacological therapies (e.g. 
antiplatelet drugs, anticoagulants, or antihypertensive drugs), referrals (e.g. to special 
care units or rehabilitations clinics), brain imaging (e.g. CT or MRI scans), typical 
symptoms (e.g. contralateral hemiparesis, dysphasia, hemianopia, etc.), or death.  
 
Nested case-control analysis 
For each case with an incident diagnosis of ischemic stroke, hemorrhagic stroke, or 
TIA we identified at random up to four control patients from the study population who 
did not develop a stroke or TIA during follow-up. We matched them to case patients 
on age (i.e. year of birth, ±3 years), sex and calendar time (i.e. the date when the 
case developed a stroke or TIA). The exposure of interest was a diagnosis of AD or 
VD prior to the index date. Exposure was further stratified by age (65–79 and ≥80 
years), sex, duration of the history of dementia (<1 and ≥1 year), and use of 
antipsychotic drugs. Use of antipsychotic drugs (in patients with AD or VD) was 
further stratified by timing of the last prescription prior to the index date (‘past’, if last 
prescription ≥90 days, or ‘current’, if last prescription <90 days), and by type of drug 
(only ‘typical’ antipsychotic drugs such as chlorpromazine, thioridazine, or 
haloperidol, only ‘atypical’ antipsychotic drugs such as olanzapine, quetiapine, or 
risperidone, or both). 
 
Statistical analysis 
In the follow-up analysis we assessed crude incidence rates (IRs) with 95% 
confidence intervals (CIs) of ischemic stroke, hemorrhagic stroke, and TIA for 
patients with AD, VD, and without dementia, stratified by age (65–79 and ≥80 years) 
and sex. We calculated corresponding age- and sex-stratified crude incidence rate 
ratios (IRRs) with 95% CIs of ischemic stroke, hemorrhagic stroke, or TIA for patients 
with AD or VD, compared to those without dementia. 
In the nested case-control analysis, we conducted conditional logistic regression 
analyses using the statistical software SAS, version 9.2 (SAS Institute, Inc., Cary, 
NC, USA). We calculated relative risk estimates as odds ratios (ORs) with 95% 
confidence intervals (CIs). The analyses were controlled for the potential confounders 
age, sex, and calendar time by matching, and further adjusted for smoking status 
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(non, current, past, or unknown), body mass index (BMI) (≤18.4, 18.5–24.9, 25–29.9, 
≥30 kg/m2 or unknown), a history of diagnosed arterial hypertension, ischemic heart 
disease, congestive heart failure, atrial fibrillation, diabetes mellitus, dyslipidemia, 
and depression, as well as for current use (i.e. the last prescription ≤90 days prior to 
the index date) of angiotensin converting enzyme (ACE) inhibitors, diuretics, 
antiplatelet drugs, anticoagulants, or statins in the multivariate model. Other potential 
confounders such as epilepsy, current use of angiotensin (AT) II receptor 
antagonists, beta blockers, calcium channel blockers, or non-steroidal anti-
inflammatory drugs (NSAIDs) were also tested in multivariate analyses; however, as 
they had no material impact (<10% change of the risk estimate) on the risk estimates 
for the association of interest, they were not included in the final multivariate model. 
 
3.4.4 Results 
The initial study population consisted of 7,086 patients with AD, 4,438 patients with 
VD, and 11,524 matched comparison subjects without dementia. VD patients were 
slightly older at the time of diagnosis than AD patients (mean age ± std.) 82.2 ± 6.6 
years vs. 80.7 ± 6.7 years), whereas the proportion of females was higher among AD 
patients (69% AD vs. 59% VD). All cardiovascular co-morbidities were less prevalent 
in patients with AD than in the corresponding comparison subjects, whereas in 
patients with VD the contrary was observed (Table 3.4-1). 
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Table 3.4-1: Characteristics of patients with Alzheimer’s disease or vascular dementia and the 
corresponding matched comparison subjects without dementia 
 AD patients 
 
Comparison 
subjects   
VD patients 
 
Comparison 
subjects   
 (n = 7086) (n = 7086)   (n = 4438) (n = 4438)   
 n (%) n (%) OR (95% CI) n (%) n (%) OR (95% CI) 
Age [years]              
65–69  410 (5.8) 411 (5.8) NA 157 (3.5) 156 (3.5) NA 
70–74 895 (12.6) 895 (12.6) NA 441 (9.9) 444 (10.0) NA 
75–79 1639 (23.1) 1638 (23.1) NA 882 (19.9) 880 (19.8) NA 
80–84 2029 (28.6) 2034 (28.7) NA 1254 (28.3) 1266 (28.5) NA 
85–90 1477 (20.8) 1475 (20.8) NA 1123 (25.3) 1114 (25.1) NA 
≥90 636 (9.0) 633 (8.9) NA 581 (13.1) 578 (13.0) NA 
               
Sex              
Male 2198 (31.0) 2198 (31.0) NA 1801 (40.6) 1801 (40.6) NA 
Female  4888 (69.0) 4888 (69.0) NA 2637 (59.4) 2637 (59.4) NA 
               
Smoking status              
None 4182 (59.0) 4029 (56.9) 1.0 (Ref) 2370 (53.4) 2497 (56.3) 1.0 (Ref) 
Current  597 (8.4) 669 (9.4) 0.9 (0.8−1.0) 522 (11.8) 382 (8.6) 1.5 (1.3–1.7) 
Past 1626 (23.0) 1692 (23.9) 0.9 (0.8−1.0) 1145 (25.8) 1133 (25.5) 1.1 (1.0–1.2) 
Unknown 681 (9.6) 696 (9.8) 0.9 (0.8−1.1) 401 (9.0) 426 (9.6) 1.0 (0.8–1.2) 
               
BMI [kg/m2]              
≤18.4 308 (4.4) 162 (2.3) 1.5 (1.2−1.8) 197 (4.4) 107 (2.4) 1.7 (1.3–2.1) 
18.5–24.9 2907 (41.0) 2243 (31.7) 1.0 (Ref) 1663 (37.5) 1456 (32.8) 1.0 (Ref) 
25–29.9 1762 (24.9) 2189 (30.9) 0.6 (0.6−0.7) 1106 (24.9) 1356 (30.6) 0.7 (0.6–0.8) 
≥30 564 (8.0) 970 (13.79 0.4 (0.4−0.5) 439 (9.90) 550 (12.4) 0.7 (0.6–0.8) 
Unknown 1545 (21.8) 1522 (21.59 0.8 (0.7−0.9) 1033 (23.3) 969 (21.8) 1.0 (0.9–1.1) 
               
Co-morbidities              
Ischemic heart disease 1255 (17.7) 1630 (23) 0.7 (0.7–0.8) 1229 (27.7) 1099 (24.8) 1.2 (1.1–1.3) 
Congestive heart failure 448 (6.3) 677 (9.6) 0.6 (0.6–0.7) 600 (13.5) 465 (10.5) 1.4 (1.2–1.5) 
Atrial fibrillation 517 (7.3) 741 (10.5) 0.7 (0.6–0.8) 814 (18.3) 503 (11.3) 1.8 (1.6–2.0) 
Hypertension 2627 (37.1) 3345 (47.2) 0.6 (0.6–0.7) 2299 (51.8) 2079 (46.9) 1.2 (1.1–1.3) 
Diabetes mellitus 570 (8.0) 747 (10.5) 0.8 (0.7–0.8) 655 (14.8) 474 (10.7) 1.5 (1.3–1.7) 
Dyslipidemia 643 (9.1) 726 (10.3) 0.9 (0.8–1.0) 453 (10.2) 419 (9.4) 1.1 (1.0–1.3) 
Depression 1527 (21.6) 1080 (15.2) 1.6 (1.4–1.7) 1121 (25.3) 636 (14.3) 2.1 (1.9–2.4) 
                          
 
AD = Alzheimer's disease, VD = Vascular dementia, OR = Odds Ratio, CI = Confidence Interval,  BMI = Body Mass Index,     
NA = Not applicable, Ref = Reference Group 
 
Incidence rates of stroke or transient ischemic attack  
After excluding patients with a history of stroke or TIA from the initial study 
population, 6,443 cases with AD, 2,302 with VD, and 9,984 dementia-free matched 
comparison subjects remained for follow-up. Within this patient group, we identified 
281 cases with an incident ischemic stroke, 139 cases with a hemorrhagic stroke, 
and 379 with a TIA. The median follow-up time was 1.7 years (interquartile range 
[IQR] 0.7–3.3). 
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The IRs of ischemic stroke for patients with AD, VD, or no dementia were 4.7/1,000 
person-years (py) (95% CI 3.8–5.9), 12.8/1,000 py (95% CI 9.8–16.8), and 5.1/1,000 
py (95% CI 4.3–5.9), respectively. The corresponding crude IRRs, stratified by sex 
and age, are displayed in Table 3.4-2.  
The IRs of hemorrhagic stroke for patients with AD, VD, or no dementia were 
2.7/1,000 py (95% CI 2.0–3.7), 9.3/1,000 py (95% CI 6.7–12.8), and 1.9/1,000 py 
(95% CI 1.5–2.5), respectively. 
The IRs of TIA for patients with AD or without dementia were similar (8.2 and 
6.2/1000 py, respectively with overlapping CIs), whereas for patients with VD the IR 
was significantly higher than for patients without dementia (IR 14.8/1,000 py) (Table 
3.4-2). 
 
Nested case-control analysis 
The analysis encompassed 281 cases with ischemic stroke and 1,124 matched 
controls, 139 cases with hemorrhagic stroke and 556 matched controls, and 379 
cases with TIA and 1515 matched controls; the respective characteristics are 
displayed in Table 3.4-3. 
While rates of ischemic and hemorrhagic stroke and TIA varied among patients with 
AD and VD, patients with AD were at a similar risk of developing an ischemic stroke 
compared to patients without dementia (adjusted OR 0.9, 95% CI 0.7–1.3). 
Stratification by duration of AD or use of antipsychotic drugs did not materially 
change this association. The adjusted OR of developing a TIA in people with AD 
compared to people with no dementia was 1.4 (95% CI 1.1–1.8). Stratification by use 
of antipsychotic drugs revealed effect modification. Cases who were currently 
exposed to atypical antipsychotics were at high risk for TIA, adj. OR for TIA 5.5 (95% 
CI 2.6–11.7), while those not exposed to antipsychotic treatment had no materially 
elevated risk (adj. OR 1.3, 95% 0.9–1.8). The adjusted OR of developing a 
hemorrhagic stroke in association with AD was 2.0 (95% CI 1.2–3.3), which was 
higher in those exposed to typical antipsychotic drugs (adj. OR 7.1, 95% CI 1.9–26.9) 
than in those not receiving antipsychotic treatment (adj. OR 1.4, 95% CI 0.7–2.7), 
although the difference did not reach statistical significance because of small 
numbers (Table 3.4-4).  
As compared with patients without dementia, patients with VD had an approximately 
twofold increased risk of developing an ischemic stroke (adj. OR 2.1, 95% CI 1.4–
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3.1) or a TIA (adj. OR 1.8, 95% CI 1.3–2.6). The adjusted OR of developing a 
hemorrhagic stroke in association with VD was 4.7 (95% CI 2.5–9.0). Stratification by 
use of antipsychotic drugs revealed a markedly higher adjusted OR of 11.1 (95% CI 
2.5–49.8) in patients receiving atypical antipsychotic drugs than in those not 
receiving antipsychotic treatment (adj. OR 4.2, 95% CI 1.6–11.0), although the 
difference did not reach statistical significance due to small numbers (Table 3.4-4).  
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Table 3.4-2: Incidence rates of ischemic or hemorrhagic stroke or transient ischemic attack in patients with Alzheimer’s disease, vascular dementia, or no 
dementia and corresponding incidence rate ratios, stratified by age and sex 
    Ischemic stroke Hemorrhagic stroke Transient ischemic attack 
 
Person-
years 
Cases 
(n=281) 
IR/1,000 person-
years (95% CI) IRR (95% CI) 
Cases 
(n=139) 
IR/1,000 person-
years (95% CI) IRR (95% CI) 
Cases 
(n=379) 
IR/1,000 person-
years (95% CI) IRR (95% CI) 
No dementia 
                   
All 30773 156 5.1 (4.3–5.9) 1.0 (Ref) 59 1.9 (1.5–2.5) 1.0 (Ref) 191 6.2 (5.4–7.1) 1.0 (Ref) 
Men 10355 55 5.3 (4.1–6.9) 1.0 (Ref) 25 2.4 (1.6–3.6) 1.0 (Ref) 70 6.8 (5.4–8.5) 1.0 (Ref) 
Women 20418 101 4.9 (4.1–6.0) 1.0 (Ref) 34 1.7 (1.2–2.3) 1.0 (Ref) 121 5.9 (5.0–7.1) 1.0 (Ref) 
Age 65–79 years 10467 38 3.6 (2.6–5.0) 1.0 (Ref) 10 1.0 (0.5–1.8) 1.0 (Ref) 50 4.8 (3.6–6.3) 1.0 (Ref) 
Age ≥80 20306 118 5.8 (4.9–7.0) 1.0 (Ref) 49 2.4 (1.8–3.2) 1.0 (Ref) 141 6.9 (5.9–8.2) 1.0 (Ref) 
                    
Alzheimer's disease 
                   
All 15688 74 4.7 (3.8–5.9) 0.9 (0.7–1.2) 43 2.7 (2.0–3.7) 1.4 (0.9–2.2) 129 8.2 (6.9–9.8) 1.3 (1.0–1.7) 
Men 4643 25 5.4 (3.7–7.9) 1.0 (0.6–1.6) 19 4.1 (2.6–6.4) 1.7 (0.9–3.2) 35 7.5 (5.4–10.5) 1.1 (0.7–1.7) 
Women 11046 49 4.4 (3.4–5.9) 0.9 (0.6–1.3) 24 2.2 (1.5–3.2) 1.3 (0.8–2.2) 94 8.5 (7.0–10.4) 1.4 (1.1–1.9) 
Age 65–79 years 5970 27 4.5 (3.1–6.6) 1.2 (0.8–2.1) 12 2.0 (1.2–3.5) 2.1 (0.9–5.0) 45 7.5 (5.6–10.1) 1.6 (1.0–2.4) 
Age ≥80 9718 47 4.8 (3.6–6.4) 0.8 (0.6–1.2) 31 3.2 (2.2–4.5) 1.3 (0.8–2.1) 84 8.6 (7.0–10.7) 1.2 (0.9–1.6) 
                    
Vascular dementia 
                   
All 3982 51 12.8 (9.8–16.8) 2.5 (1.6–3.8) 37 9.3 (6.7–12.8) 4.8 (2.6–9.0) 59 14.8 (11.5–19.1) 2.4 (1.6–3.5) 
Men 1468 25 17.0 (11.6–25.0) 3.2 (1.6–6.1) 14 9.5 (5.7–15.9) 3.9 (1.5–10.1) 24 16.3 (11.0–24.2) 2.4 (1.3–4.4) 
Women 2513 26 10.3 (7.1–15.1) 2.1 (1.2–3.6) 23 9.2 (6.1–13.7) 5.5 (2.4–12.5) 35 13.9 (10.0–19.3) 2.3 (1.4–3.8) 
Age 65–79 years 1244 21 16.9 (11.1–25.7) 4.6 (2.0–10.4) 8 6.4 (3.3–12.6) 6.7 (1.5–29.8) 15 12.1 (7.3–19.8) 2.5 (1.1–5.5) 
Age ≥80 2738 30 11.0 (7.7–15.6) 1.9 (1.1–3.1) 29 10.6 (7.4–15.2) 4.4 (2.2–8.6) 44 16.1 (12.0–21.5) 2.3 (1.5–3.6) 
                                  
 
IR = Incidence Rate, IRR = Incidence Rate Ratio, CI = Confidence Interval, Ref = Reference Group 
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Table 3.4-3: Characteristics of cases with ischemic or hemorrhagic stroke or transient ischemic attack and corresponding controls 
  
Ischemic stroke Hemorrhagic stroke Transient ischemic attack 
 
 
Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* 
 
(n = 281) (n = 1124)     (n = 139) (n = 556)     (n = 379) (n = 1515)     
 
n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) 
Age [years]                             
65−79 105 (37.4) 420 (37.4) NA  NA   58 (41.7) 232 (41.7) NA  NA   129 (34.0) 516 (34.1) NA NA 
≥80 176 (62.6) 704 (62.6) NA  NA   81 (58.3) 324 (58.3) NA  NA   250 (66.0) 999 (65.9) NA NA 
 
                            
Sex                             
Male 86 (30.6) 322 (28.7) NA  NA   30 (21.6) 124 (22.3) NA  NA   110 (29.0) 435 (28.7) NA NA 
Female 195 (69.4) 802 (71.4) NA  NA   109 (78.4) 432 (77.7) NA  NA   269 (71.0) 1080 (71.3) NA NA 
 
                            
Smoking status                             
None 161 (57.3) 645 (57.4) 1.0 (Ref) 1.0 (Ref) 70 (50.4) 319 (57.4) 1.0 (Ref) 1.0 (Ref) 217 (57.3) 836 (55.2) 1.0 (Ref) 1.0 (Ref) 
Current  34 (12.1) 111 (9.9) 1.2 (0.8−1.9) 1.4 (0.9−2.2) 18 (13.0) 48 (8.6) 1.7 (0.9−3.1) 2.7 (1.4−5.5) 38 (10.0) 144 (9.5) 1.0 (0.7−1.5) 0.9 (0.6−1.4) 
Past 55 (19.6) 229 (20.4) 1.0 (0.7−1.4) 0.9 (0.7−1.3) 29 (20.9) 118 (21.2) 1.1 (0.7−1.8) 1.1 (0.6−1.9) 79 (20.8) 316 (20.9) 1.0 (0.7−1.3) 0.9 (0.7−1.3) 
Unknown 31 (11.0) 139 (12.4) 0.9 (0.6−1.4) 0.8 (0.5−1.4) 22 (15.8) 71 (12.8) 1.4 (0.8−2.6) 1.8 (0.9−3.8) 45 (11.9) 219 (14.5) 0.8 (0.5−1.1) 0.8 (0.5−1.1) 
 
                            
BMI [kg/m2]                             
≤18.4 5 (1.8) 15 (1.3) 1.3 (0.5−3.7) 1.4 (0.5−4.1) 1 (0.7) 15 (2.7) 0.3 (0.0−2.2) 0.2 (0.0−1.7) 8 (2.1) 32 (2.1) 0.9 (0.4−2.0) 0.8 (0.4−1.9) 
18.5−24.9 99 (35.2) 396 (35.2) 1.0 (Ref) 1.0 (Ref) 47 (33.8) 198 (35.6) 1.0 (Ref) 1.0 (Ref) 135 (35.6) 493 (32.5) 1.0 (Ref) 1.0 (Ref) 
25−29.9 76 (27.1) 343 (30.5) 0.9 (0.6−1.2) 0.9 (0.6−1.2) 33 (23.7) 141 (25.4) 1.0 (0.6−1.6) 0.9 (0.5−1.6) 107 (28.2) 426 (28.1) 0.9 (0.7−1.2) 0.9 (0.7−1.3) 
≥30 31 (11.0) 101 (9.0) 1.2 (0.8−1.9) 1.1 (0.7−1.8) 16 (11.5) 56 (10.1) 1.2 (0.6−2.3) 1.0 (0.4−2.1) 32 (8.4) 165 (10.9) 0.7 (0.5−1.1) 0.7 (0.4−1.1) 
Unknown 70 (24.9) 269 (23.9) 1.0 (0.7−1.5) 1.3 (0.8−1.9) 42 (30.2) 146 (26.3) 1.3 (0.8−2.0) 1.2 (0.7−2.2) 97 (25.6) 399 (26.3) 0.9 (0.7−1.2) 1.0 (0.7−1.4) 
 
                            
Co-morbidities                             
CHF 70 (24.9) 242 (21.5) 1.2 (0.9−1.7) 1.1 (0.8−1.6) 50 (36.0) 120 (21.6) 2.1 (1.4−3.2) 1.5 (0.9−2.6) 101 (26.7) 318 (21.0) 1.4 (1.1−1.8) 1.1 (0.8−1.5) 
Atrial fibrillation 30 (10.7) 111 (9.9) 1.1 (0.7−1.7) 0.9 (0.5−1.4) 29 (20.9) 56 (10.1) 2.4 (1.5−4.1) 1.5 (0.8−2.8) 42 (11.1) 136 (9.0) 1.3 (0.9−1.8) 1.0 (0.7−1.6) 
IHD 49 (17.4) 108 (9.6) 2.0 (1.4−2.9) 2.5 (1.6−3.8) 33 (23.7) 62 (11.2) 2.4 (1.5−3.8) 1.8 (1.0−3.3) 73 (19.3) 137 (9.0) 2.4 (1.7−3.2) 2.3 (1.6−3.3) 
Hypertension 156 (55.5) 513 (45.6) 1.5 (1.2−2.0) 1.5 (1.1−2.0) 71 (51.1) 233 (41.9) 1.5 (1.0−2.2) 1.4 (0.9−2.4) 179 (47.2) 664 (43.8) 1.2 (0.9−1.5) 1.1 (0.8−1.5) 
Diabetes mellitus 34 (12.1) 117 (10.4) 1.2 (0.8−1.8) 1.1 (0.7−1.8) 20 (14.4) 44 (7.9) 2.0 (1.1−3.6) 1.3 (0.7−2.6) 44 (11.6) 180 (11.9) 1.0 (0.7−1.4) 0.9 (0.6−1.3) 
Dyslipidemia 38 (13.5) 108 (9.6) 1.5 (1.0−2.3) 1.5 (0.9−2.3) 10 (7.2) 43 (7.7) 0.9 (0.4−1.9) 0.6 (0.2−1.4) 41 (10.8) 138 (9.1) 1.2 (0.8−1.8) 1.0 (0.7−1.5) 
Depression 56 (19.9) 211 (18.8) 1.1 (0.8−1.5) 1.1 (0.8−1.5) 39 (28.1) 95 (17.1) 1.9 (1.2−3.0) 1.7 (1.1−2.8) 85 (22.4) 275 (18.2) 1.3 (1.0−1.7) 1.2 (0.9−1.6) 
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Table 3.4-3 cont. 
  
Ischemic stroke Hemorrhagic stroke Transient ischemic attack 
 
 
Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* 
 
(n = 281) (n = 1124)     (n = 139) (n = 556)     (n = 379) (n = 1515)     
 
n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) 
Drugs                             
ACE inhibitors 43 (15.3) 203 (18.1) 0.9 (0.6−1.3) 0.7 (0.5−1.1) 38 (27.3) 97 (17.5) 2.2 (1.4−3.4) 1.5 (0.9−2.7) 78 (20.6) 276 (18.2) 1.2 (0.9−1.6) 0.9 (0.7−1.3) 
Diuretics 113 (40.2) 393 (35.0) 1.5 (1.1−2.0) 1.2 (0.8−1.7) 57 (41.0) 184 (33.1) 2.1 (1.3−3.5) 1.1 (0.6−2.1) 149 (39.3) 566 (37.4) 1.3 (1.0−1.7) 1.1 (0.8−1.6) 
Statins 48 (17.1) 187 (16.6) 1.0 (0.7−1.5) 0.9 (0.6−1.4) 34 (24.5) 87 (15.7) 2.0 (1.2−3.3) 1.3 (0.7−2.5) 72 (19.0) 265 (17.5) 1.2 (0.9−1.7) 1.0 (0.7−1.4) 
Antiplatelets 27 (9.6) 86 (7.7) 1.3 (0.8−2.1) 1.2 (0.7−1.9) 19 (13.7) 46 (8.3) 1.9 (1.1−3.4) 1.6 (0.8−3.2) 61 (16.1) 130 (8.6) 2.1 (1.5−3.0) 2.0 (1.4−2.9) 
Anticoagulants 9 (3.2) 42 (3.7) 0.9 (0.4−1.8) 0.5 (0.2−1.0) 17 (12.2) 11 (2.0) 7.2 (3.2−16.2) 4.3 (1.6−11.8) 20 (5.3) 63 (4.2) 1.3 (0.8−2.3) 0.8 (0.4−1.4) 
                                                  
 
*Adjusted for all covariates listed in this table. CHF = Congestive Heart Failure, IHD = Ischemic Heart Disease, ACE = Angiotensin Converting Enzyme , OR = Odds Ratio, CI = Confidence Interval, 
Ref = Reference Group
DEMENTIA PROJECT                                                STROKE IN ALZHEIMER’S DISEASE 
95 
Table 3.4-4: Risk of developing ischemic or hemorrhagic stroke or transient ischemic attack in patients with Alzheimer’s disease or vascular dementia, 
stratified by age, sex, duration of dementia, and current use of typical or atypical antipsychotic drugs 
  
Ischemic stroke Hemorrhagic stroke Transient ischemic attack 
 
 
Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* 
 
(n = 281) (n = 1124)     (n = 139) (n = 556)     (n = 379) (n = 1515)     
  
n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) 
                                   
No dementia 156 (55.5) 657 (58.5) 1.0 (Ref) 1.0 (Ref) 59 (42.5) 342 (61.5) 1.0 (Ref) 1.0 (Ref) 191 (50.4) 916 (60.5) 1.0 (Ref) 1.0 (Ref) 
 
                            
Alzheimer's 
disease 74 (26.3) 365 (32.5) 0.8 (0.6–1.1) 0.9 (0.7–1.3) 43 (30.9) 171 (30.8) 1.4 (0.9–2.2) 2.0 (1.2–3.3) 129 (34.0) 457 (30.2) 1.3 (1.0–1.7) 1.4 (1.1–1.8) 
Sex                             
Male 25 (8.9) 119 (10.6) 1.0 (0.6–1.6) 1.0 (0.6–1.7) 19 (13.7) 70 (12.6) 1.6 (0.8–3.1) 2.8 (1.3–6.0) 35 (9.2) 141 (9.3) 1.1 (0.7–1.7) 1.1 (0.7–1.8) 
Female 49 (17.4) 246 (21.9) 0.8 (0.5–1.1) 0.9 (0.6–1.3) 24 (17.3) 101 (18.2) 1.3 (0.7–2.2) 1.7 (0.9–3.1) 94 (24.8) 316 (20.9) 1.4 (1.1–1.9) 1.5 (1.1–2.1) 
                             
Age [years]                             
65–79 27 (9.6) 105 (9.3) 1.2 (0.7–2.1) 1.3 (0.8–2.3) 12 (8.6) 40 (7.2) 1.8 (0.8–4.2) 3.3 (1.2–9.1) 45 (11.9) 124 (8.2) 1.9 (1.2–2.9) 2.0 (1.3–3.1) 
≥80 47 (16.7) 260 (23.1) 0.7 (0.5–1.0) 0.8 (0.5–1.1) 31 (22.3) 131 (23.6) 1.3 (0.8–2.1) 1.8 (1.0–3.0) 84 (22.2) 333 (22.0) 1.1 (0.8–1.5) 1.2 (0.9–1.6) 
                             
Duration [years]                             
<1 29 (10.3) 144 (12.8) 0.8 (0.5–1.3) 1.0 (0.6–1.5) 14 (10.1) 65 (11.7) 1.2 (0.6–2.3) 1.5 (0.8–3.0) 39 (10.3) 167 (11.0) 1.1 (0.7–1.6) 1.1 (0.7–1.6) 
≥1 45 (16.0) 221 (19.7) 0.8 (0.6–1.2) 0.9 (0.6–1.3) 29 (20.9) 106 (19.1) 1.5 (0.9–2.5) 2.5 (1.4–4.4) 90 (23.8) 290 (19.1) 1.5 (1.1–1.9) 1.6 (1.2–2.1) 
                             
Antipsychotics                             
No use 41 (14.6) 212 (18.9) 0.8 (0.6–1.2) 0.9 (0.6–1.4) 17 (12.2) 100 (18.0) 0.9 (0.5–1.7) 1.4 (0.7–2.7) 65 (17.2) 251 (16.6) 1.2 (0.9–1.7) 1.3 (0.9–1.8) 
Past use 16 (5.7) 90 (8.0) 0.7 (0.4–1.3) 0.7 (0.4–1.3) 12 (8.6) 42 (7.6) 1.6 (0.8–3.2) 2.0 (0.9–4.6) 28 (7.4) 142 (9.4) 0.9 (0.6–1.4) 0.9 (0.6–1.5) 
Current use 17 (6.1) 63 (5.6) 1.1 (0.6–1.9) 1.1 (0.6–2.0) 14 (10.1) 29 (5.2) 2.7 (1.4–5.4) 4.0 (1.8–8.9) 36 (9.5) 64 (4.2) 2.7 (1.7–4.2) 2.9 (1.8–4.6) 
Typical only 4 (1.4) 17 (1.5) 1.0 (0.3–2.9) 1.1 (0.3–3.3) 5 (3.6) 8 (1.4) 3.7 (1.1–11.8) 7.1 (1.9–26.9) 8 (2.1) 23 (1.5) 1.6 (0.7–3.7) 1.8 (0.8–4.2) 
Atypical only 7 (2.5) 20 (1.8) 1.4 (0.6–3.4) 1.4 (0.6–3.5) 1 (0.7) 10 (1.8) 0.6 (0.1–5.2) 0.8 (0.1–8.5) 16 (4.2) 16 (1.1) 4.8 (2.3–9.8) 5.5 (2.6–11.7) 
Both 6 (2.1) 26 (2.3) 1.0 (0.8–1.2) 1.0 (0.8–1.2) 8 (5.8) 11 (2.0) 1.3 (1.1–1.5) 1.3 (1.1–1.7) 12 (3.2) 25 (1.7) 1.2 (1.0–1.4) 1.2 (1.0–1.4) 
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Table 3.4-4 cont. 
  
Ischemic stroke Hemorrhagic stroke Transient ischemic attack 
 
 
Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* Cases Controls Unadjusted Adjusted* 
 
(n = 281) (n = 1124)     (n = 139) (n = 556)     (n = 379) (n = 1515)     
  
n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) n (%) n (%) OR (95% CI) OR (95% CI) 
                                   
No dementia 156 (55.5) 657 (58.5) 1.0 (Ref) 1.0 (Ref) 59 (42.5) 342 (61.5) 1.0 (Ref) 1.0 (Ref) 191 (50.4) 916 (60.5) 1.0 (Ref) 1.0 (Ref) 
 
                            
Vascular 
dementia 51 (18.2) 102 (9.1) 2.1 (1.5–3.1) 2.1 (1.4–3.1) 37 (26.6) 43 (7.7) 5.1 (3.0–8.8) 4.7 (2.5–9.0) 59 (15.6) 142 (9.4) 2.0 (1.4–2.8) 1.8 (1.3–2.6) 
Sex                             
Male 25 (8.9) 41 (3.7) 2.9 (1.6–5.1) 2.9 (1.6–5.3) 14 (10.1) 12 (2.2) 7.2 (2.9–18.1) 8.3 (2.6–25.8) 24 (6.3) 60 (4.0) 1.8 (1.0–3.1) 1.7 (1.0–3.0) 
Female 26 (9.3) 61 (5.4) 1.7 (1.0–2.8) 1.7 (1.0–2.8) 23 (16.6) 31 (5.6) 4.2 (2.2–8.2) 3.6 (1.6–7.8) 35 (9.2) 82 (5.4) 2.1 (1.3–3.3) 1.8 (1.2–2.9) 
                             
Age [years]                             
65–79 21 (7.5) 37 (3.3) 2.8 (1.5–5.3) 2.7 (1.4–5.2) 8 (5.8) 4 (0.7) 12.7 (3.2–50.2) 7.0 (1.4–35.2) 15 (4.0) 31 (2.1) 2.5 (1.3–4.8) 2.8 (1.4–5.5) 
≥80 30 (10.7) 65 (5.8) 1.8 (1.1–2.9) 1.9 (1.2–3.1) 29 (20.9) 39 (7.0) 4.2 (2.4–7.6) 4.3 (2.1–8.7) 44 (11.6) 111 (7.3) 1.8 (1.2–2.7) 1.6 (1.0–2.4) 
                             
Duration [years]                             
<1 30 (10.7) 51 (4.5) 2.5 (1.5–4.0) 2.6 (1.6–4.3) 13 (9.4) 18 (3.2) 4.0 (1.9–8.8) 3.2 (1.2–8.4) 24 (6.3) 82 (5.4) 1.4 (0.9–2.2) 1.2 (0.7–2.0) 
≥1 21 (7.5) 51 (4.5) 1.7 (1.0–2.9) 1.6 (0.9–2.9) 24 (17.3) 25 (4.5) 6.0 (3.1–11.8) 6.1 (2.8–13.5) 35 (9.2) 60 (4.0) 2.9 (1.8–4.7) 2.8 (1.7–4.6) 
                             
Antipsychotics                             
No use 28 (10.0) 54 (4.8) 2.1 (1.3–3.5) 2.3 (1.4–3.8) 13 (9.4) 20 (3.6) 4.0 (1.9–8.6) 4.2 (1.6–11.0) 24 (6.3) 78 (5.2) 1.5 (0.9–2.4) 1.4 (0.9–2.4) 
Past use 19 (6.8) 25 (2.2) 3.4 (1.8–6.5) 3.1 (1.6–6.2) 11 (7.9) 9 (1.6) 6.7 (2.6–17.4) 4.7 (1.6–14.1) 17 (4.5) 33 (2.2) 2.5 (1.4–4.6) 2.1 (1.1–4.0) 
Current use 4 (1.4) 23 (2.1) 0.7 (0.2–2.1) 0.7 (0.2–2.2) 13 (9.4) 14 (2.5) 5.8 (2.5–13.4) 5.3 (2.0–13.6) 18 (4.8) 31 (2.1) 2.8 (1.5–5.1) 2.5 (1.3–4.7) 
Typical only 0 (0.0) 9 (0.8)  NA  NA 4 (2.9) 5 (0.9) 4.0 (1.0–15.4) 2.3 (0.5–10.7) 6 (1.6) 10 (0.7) 3.1 (1.1–8.7) 2.9 (1.0–8.6) 
Atypical only 2 (0.7) 8 (0.7) 1.1 (0.2–5.2) 1.1 (0.2–5.7) 6 (4.3) 4 (0.7) 9.4 (2.6–35.0) 11.1 (2.5–49.8) 6 (1.6) 12 (0.8) 2.4 (0.9–6.6) 1.9 (0.7–5.5) 
Both 2 (0.7) 6 (0.5) 1.4 (0.3–7.0) 1.4 (0.3–7.4) 3 (2.2) 5 (0.9) 4.2 (0.9–19.7) 5.2 (0.9–30.8) 6 (1.6) 9 (0.6) 3.1 (1.1–8.8) 3.0 (1.0–9.0) 
                                                  
 
*
 Adjusted for smoking, BMI, ischemic heart disease, congestive heart failure, atrial fibrillation, hypertension, diabetes mellitus, dyslipidemia, depression, and use of angiotensin converting enzyme 
(ACE) inhibitors, diuretics, antiplatelets, anticoagulants and statins. OR = Odds Ratio, CI = Confidence Interval, Ref = Reference Group 
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3.4.5 Discussion 
We found that patients with AD did not have a materially altered risk of ischemic 
stroke compared to those without dementia, whereas patients with VD had an about 
twofold increased risk. We further found that patients with AD had a twofold higher 
risk of developing a hemorrhagic stroke than patients without dementia. Of note, 
cerebral amyloid angiopathy (CAA) is an important cause of sporadic hemorrhagic 
stroke in the elderly166, and it has been suggested that presence of the apolipoprotein 
E ε4 allele – which has also been linked to the development of late-onset AD73 – may 
accelerate the process that leads to CAA-related hemorrhagic stroke.167 
A previous population-based cohort study of 1,551 subjects aged ≥75 years with no 
stroke history found similar results. The risks of incident stroke for patients with mild 
dementia or cognitive impairment in the study were 2.6 (95% CI 1.2–5.7) and 2.0 
(95% CI 1.0–3.8), respectively.152 Of importance, these authors did not stratify by 
dementia subtypes, as we did. They found that - within the group of patients with 
cognitive impairment - those who developed a stroke tended to have a higher 
prevalence of vascular risk factors (such as hypertension, heart disease, or diabetes 
mellitus) compared to those who did not.152 This supports our findings that AD 
patients who had no increased risk of developing an ischemic stroke, had a lower 
prevalence of vascular risk factors than patients with VD, who in turn had an about 
twofold higher risk. Since VD by definition is associated with cerebrovascular 
disease78 and, according to our data, VD patients have a higher prevalence of 
cardiovascular risk factors than patients without dementia, it may be that VD patients 
suffered from cerebral microangiopathy prior to developing an ischemic stroke and 
were therefore at a higher risk of ischemic stroke than non-demented subjects. In 
addition, since these authors152 did not differentiate between ischemic stroke, 
hemorrhagic stroke or TIA, a direct comparison of the results is difficult. However, 
ischemic stroke is more common than hemorrhagic stroke168 and thus may have 
accounted for the majority of stroke cases in that study.152 
Regarding the role of antipsychotic drugs on the risk of developing stroke or TIA, we 
found that AD patients who received atypical antipsychotic drugs only, had a higher 
risk of developing a TIA than AD patients who did not receive antipsychotic drug 
treatment. For patients with VD there was no difference between users of typical or 
atypical antipsychotic drugs and those who did not receive antipsychotic treatment. 
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There are several observational studies161-163,169 that examined the association 
between exposure to typical or atypical antipsychotic drugs in patients with dementia 
and the risk of cerebrovascular events, but to our knowledge there is only one 
study170 that also stratified by different dementia types, i.e. AD vs. VD. In this 
particular cohort study of 14,029 US veterans aged ≥65 years, diagnosed with AD or 
VD, neither use of atypical nor typical antipsychotics in patients with AD was 
associated with an increased risk of developing a cerebrovascular event, compared 
to non-users of antipsychotic drugs; for patients with VD there was no significant 
difference in risk between users of atypical compared to typical antipsychotic drugs, 
but there was a suggestion of an increased risk of developing a cerebrovascular 
event associated with VD, which was not present in patients with AD. Although the 
latter finding largely supports our results of a significantly higher risk of developing a 
stroke in patients with VD, as compared to patients with AD, the study was limited by 
a relatively short follow-up period of 18 months (in which less than 4% of the study 
population developed a cerebrovascular event). Additionally, the authors of this study 
did not differentiate between stroke and TIA in their study. Since stroke itself is not a 
uniform condition, combining these conditions to one “cerebrovascular group” may 
have masked subtle differences in relative risk estimates, as found in our study.  
Our finding of an increased TIA risk in AD patients exposed only to atypical 
antipsychotic drugs is supported by reports of adverse drug events in association 
with use of atypical antipsychotics from randomized controlled trials that aimed at 
studying the efficacy of these drugs to treat behavioral symptoms in patients with AD. 
In these trials, a TIA was found to be the only171,172 or the most frequent173 
cerebrovascular adverse drug event. 
The results of our study must be interpreted in the light of some limitations. First, we 
identified a large number of potential stroke or TIA cases based on recorded codes. 
As we were not able to review each patient’s record to verify the stroke or TIA 
diagnosis, we used a stringent predefined algorithm to increase the likelihood of 
including cases with a valid diagnosis of stroke or TIA. However, some residual 
misclassification cannot be ruled out.  Further, we could not assess the severity of 
AD or VD to test whether severity of dementia altered the risk of developing a stroke 
or a TIA, because we had no information on the patients’ cognitive status from the 
record. However, as duration of symptoms has been related to dementia severity,149 
we used duration of the disease as a rough proxy for severity.  
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The major strength of our study is that we used a large and well-established primary-
care database which has been validated numerous times in the past.103,104 Since 
stroke and TIA are not common in patients with AD or VD (only about 4% of all AD 
patients and about 7% of all VD patients in our study developed a stroke or TIA 
during follow-up), a large database such as the CPRD was necessary to obtain an 
adequate number of patients to detect potential differences between users and non-
users of (typical or atypical) antipsychotics. Furthermore, we used a sophisticated 
and validated algorithm to identify only well-defined AD or VD cases for inclusion in 
the study population. 
In summary, we found that patients with AD did not have a materially different risk of 
developing an ischemic stroke compared to patients without dementia, whereas 
patients with VD had an about twofold increased risk. AD patients receiving atypical 
antipsychotic drugs only had a higher risk of developing a TIA than AD patients not 
receiving any antipsychotic drug treatment, whereas for patients with VD there was 
no significant difference between users of atypical or typical antipsychotic drugs and 
those not receiving antipsychotic treatment. 
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4  DISCUSSION, CONCLUSIONS, AND OUTLOOK 
4.1 DISCUSSION 
The overall aim of this thesis was to contribute to the understanding of the natural 
history of the two most common dementia subtypes AD and VD, by using data from 
GPRD, a large and well-established physician-based primary care database from the 
UK. A detailed discussion of the main findings of this thesis is provided in the 
corresponding sections of the Studies 3.1–3.4. In this chapter some general strengths 
and limitations of the GPRD will be discussed and illustrated with examples from the 
different studies. 
 
4.1.1 Strengths of the General Practice Research Database 
Size 
The GPRD encompasses data on over five million active research quality patients 
from the UK who are registered with selected GPs. This large number of patients 
translates into more than 45 million py of research quality data.100 This large size of 
the database allows researchers to study rare outcomes with an incidence rate of 
less than one per 10,000 persons per year with enough statistical power.174 As an 
example: based on limited evidence from case reports, AChEIs have been suspected 
to rarely provoke seizures in patients with AD.143,144 This is supported by two small 
RCTs assessing the efficacy of donepezil to improve memory in patients with 
epilepsy that found a small but non-significant difference in seizure frequency 
between those treated with donepezil and those treated with placebo.147,148 However, 
since occurrence of seizures or epilepsy in AD is overall uncommon,138 one would 
require a much larger sample size (and/or a longer observation period) to detect a 
statistically significant difference among users of AChEIs compared to nonusers, if it 
exists. Notably, in our study (3.3) that included a relatively large sample of almost 
7,000 AD patients observed over a median follow-up time of 1.5 years, we did not 
find a statistically significant difference. 
 
Population-based data 
The GPRD represents a defined population, which allows researchers to study all 
patients with a certain disease (i.e. the cases) and enables them to study control 
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patients from the same source population from which the cases were derived. This 
minimizes selection bias (cf. chapter 1.1.4) and improves the validity of the study.12 
Additionally, patients in the GPRD cover about 8% of the UK population100 and are 
broadly representative of the general UK population in terms of age, sex, geographic 
distribution, and annual turnover rate. As an example: in Study 3.3 we estimated the 
relative risk of developing seizures in patients with AD. Our relative risk estimate (OR 
6.6) was somewhat lower than the corresponding estimates reported in two previous 
studies (RR 10.0 and HR 8.06),134,138 although reported confidence intervals in these 
two studies were wide and included the point estimate reported in our study. 
However, in both these comparison studies AD cases were recruited from special 
care facilities or specialized diagnostic and treatment centers; thus, these patients 
were presumably at a more advanced stage of their disease compared to demented 
patients selected from the general population in primary care, as in our study. As 
more severe and advanced stages of AD have been reported to be associated with a 
greater risk of seizures or epilepsy,136,137 these patients were probably more likely to 
have seizures or epilepsy than a sample of AD patients derived from the general 
population. 
 
Access to original medical records 
Investigators who work with the GPRD have the opportunity to obtain anonymized 
photocopies of the patient’s paper medical record. This allows investigators to verify 
the information recorded on death certificates or letters from specialists. Additionally, 
there’s the possibility to send out questionnaires to the GPs asking them for 
additional patient information that has not been recorded in the electronic medical 
file. Sometimes it’s even possible to have questionnaires completed by individual 
patients by working through their GP.12,174 As an example: All the AD and VD cases 
that formed (together with their corresponding dementia-free controls) the study 
population in the studies of this thesis were identified through a specially developed 
algorithm. To validate this algorithm we sent out a questionnaire to GPs for a random 
sample of potential AD and VD cases to get additional information on the clinical 
circumstances and the diagnostic steps taken. The response rate of the GPs was 
almost 80%, a number which has also been confirmed by other studies.175 
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4.1.2 Limitations of the General Practice Research Database 
Missing data 
In fact the information recorded by the GP is expected to be complete. However, 
information from specialists as well as events that occur in the hospital may not be 
fully captured in the electronic patient record. Communications from specialists, 
discharge letters from hospitals, and laboratory test results are often received in hard 
copy and must be manually entered into the practice computer. Since this can be 
time-consuming, some practices may only enter information that will affect the future 
care of the patient. Therefore only abnormal test results may be entered into the 
computer. Additionally, information on treatments that are restricted by the National 
Health Service (NHS) to specialist care (e.g. chemotherapy in the hospital) may not 
be captured in the patient file. Information about over-the-counter (OTC) medication 
is not readily available in the GPRD. Furthermore, data on important confounders 
such as dietary or exercise habits is largely missing and information on other lifestyle 
factors such as smoking, BMI, or alcohol consumption is not recorded for all 
patients.12,174 As an example: in Study 3.2, where we explored the risk of developing 
AD in patients with diabetes mellitus treated with metformin or with other antidiabetic 
drugs, we were not able to adjust for certain potential confounders such as ApoE ε4 
allele,73 level of education,132 or certain lifestyle factors such as physical activity133 or 
dietary habits.68 However, we adjusted for BMI which is to some degree related to 
physical activity and dietary habits.  
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4.2 CONCLUSIONS  
The aim of this thesis was to increase knowledge on the natural history of the two 
most common dementia forms AD and VD, thereby focusing on the effect of certain 
drug therapies as potential risk or protective factors for these diseases or 
complications thereof. In the following, the main findings are briefly summarized: 
 
• The IR of AD was higher for women than for men, whereas for VD no 
difference in sex-specific IR was observed. 
• The prevalence of all CV co-morbidities and exposure to CV drugs was lower 
in patients with AD than in those without dementia, whereas the opposite was 
true for VD. This may be a true finding or the result of diagnostic bias, i.e. 
demented patients with CV diseases may be more likely to be diagnosed with 
VD than AD. 
• Long-term users of metformin had a slightly increased risk of developing AD 
as compared to non-users, but there was no consistent trend with increasing 
duration of use.  
• Use of other antidiabetic drugs such as sulfonylureas, thiazolidinediones, or 
insulin was not associated with an altered risk of developing AD. 
• Seizures or epilepsy were substantially more common in patients with AD and 
VD than in dementia-free patients. 
• AD patients with longer standing (≥3 years) had a slightly higher risk of 
developing seizures or epilepsy than those with a shorter disease duration, 
while in patients with VD the contrary was observed. 
• Patients with AD did not have a materially altered risk of developing an 
ischemic stroke compared to those without dementia, whereas patients with 
VD had an about twofold increased risk. 
• AD patients receiving atypical antipsychotic drugs only had a higher risk of 
developing a TIA than AD patients not receiving any antipsychotic drug 
treatment, whereas for patients with VD there was no significant difference 
between users of atypical or typical antipsychotic drugs and those not 
receiving antipsychotic treatment. 
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4.3 OUTLOOK 
There are currently two ongoing studies assessing incidence rates of new-onset 
diseases (complications) in patients with AD or VD and studying risk factors for the 
development of such complications. The first study focuses on fractures. Evidence 
from the literature suggests that AD patients have a higher risk of sustaining a 
fracture, particularly of the hip, as compared to non-demented elderly people.176-178 
Hip fractures represent about 50% of all fracture types in patients with AD,176 and the 
association between AD and hip fractures has been found to be independent of other 
important risk factors for fractures such as osteoporosis or falling.179 However, little is 
known about specific risk factors (e.g. age, sex, severity of dementia, etc.) of 
sustaining a hip fracture in patients with AD and specific risk estimates for patients 
with VD are lacking, too.  
The second ongoing study focuses on depression. Depression is one of the most 
common psychiatric disorders observed in patients with AD. Many studies 
investigated the frequency of depression or depressive disorders in patients with AD 
and reported prevalence rates ranging between 30–50%.180 By contrast, there are 
only few studies assessing the incidence of depression in patients with AD and 
estimates thereof vary considerably.181-184  
Furthermore, there’s an interesting study in preparation for submission that explored 
the risk of developing AD in association with a history of influenza infection(s). This 
against the background that several epidemiological studies suggest a potential 
involvement of viral pathogens in the development of AD.185-188 However, while 
recent research focuses on herpes simplex virus type 1 (HSV-1),189,190 the role of 
influenza infection is largely unknown. 
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6 APPENDIX 
 
QUESTIONNAIRE FOR GENERAL PRACTITIONERS 
 
 
Study into Dementia: Questionnaire for £ 
 
Please tick the appropriate box 
 
1) Does the patient with the ID number …………have dementia? 
 Yes 
 No 
 
2) Did you as GP perform any test(s) to assess the level of cognitive impairment? 
 Yes 
 No 
If ‘Yes’, which test(s)? (Several answers possible) 
 Mini Mental State Examination (MMSE) 
 6-Item Cognitive Impairment Test (6-CIT) 
 General Practitioner Assessment of Cognition (GPCOG) 
 Abbreviated Mental Test (7-Minute Screen) 
 Clock Drawing Test (CDT) 
 Other, please specify ______________________________________  
 
3) Has the dementia diagnosis been confirmed by a specialist (e.g. geriatrician, 
psychiatrist, neurologist, psychologist, etc.)? 
 Yes 
 No 
If ‘Yes’, by which method? (Several answers possible) 
 Neuropsychological assessment 
 Magnetic Resonance Imaging (MRI) 
 Computed Tomography (CT) 
 Single Photon Emission Computed Tomography (SPECT) 
 Cerebrospinal fluid (CSF)-biomarkers 
 Other, please specify  ______________________________________ 
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4) Has the subtype of dementia been further specified? 
 Yes 
 No 
If ‘Yes’ what is the subtype of dementia? 
 Alzheimer’s disease 
 Vascular dementia 
 Mixed Alzheimer’s disease/Vascular dementia 
 Lewy body dementia 
 Frontotemporal dementia (Pick’s disease) 
 Other, please specify  ______________________________________ 
 
5) When was the dementia (including subtype) diagnosed? 
 _ _ / _ _ _ _  (MM/YYYY) 
  
6) Does or did the patient receive regular pharmacological treatment (i.e. 3 or more 
prescriptions) for dementia which is not recorded in the electronic patient file (e.g. 
prescriptions issued by a specialized clinic)? 
 Yes 
 No 
If ‘Yes’, which drug?  
 Donepezil 
 Rivastigmine 
 Galantamine 
 Memantine 
 Other, please specify  ______________________________________ 
 
 
Please also provide photocopies of all relevant hospital summaries, discharge letters 
and test results that can verify the diagnosis. 
 
Many thanks for your time in completing this questionnaire. 
Please now return it in the freepost envelope provided. 
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